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Renin is the rate-limiting enzyme involved in renin-angiotensin system. Renin 
elevation occurs during pathological states of renal ischemia (renin in systematic circulation) 
or cardiac remodeling (renin in local tissue). Our present study clearly demonstrated the 
ability of H2S to suppress renin elevation by preventing renin release from renin-rich kidney 
granular cells or cardiac mast cells, both by attenuating cAMP increment, thus limiting the 
detrimental effects of renin in renal hypertension or heart failure, respectively.  
Our results shed new lights to the underlying mechanisms of H2S-induced protection, 
and support H2S as a promising therapeutic treatment against renin-dependent pathological 
diseases.              
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Chatper 1. Introduction on H2S 
1.1 General Overview 
 For more than a century, hydrogen sulfide (H2S) has always been seen as a toxic gas. 
The past decade has seen an exponential growth of scientific interest in the physiological and 
pathological significance of H2S, and it is now well recognized as the third member of 
gasotransmitters discovered subsequent to nitric oxide (NO) and carbon monoxide (CO). H2S 
qualifies as an endogenous gaseous mediator because 1) it can be endogenously synthesized 
in organs and tissues; 2) it exists in plasma and tissues; and 3) it is implicated in many 
physiological and pathological functions. Most research efforts have focused on its role in the 
cardiovascular system and central nervous system, making these two areas most well studied 
till date. In the heart, H2S induces cardioprotective effects1, 2; In vascular tissues, H2S induces 
both vasorelaxation 3-10 as well as vasoconstriction 3, 8, 9, 11, depending on the concentration of 
H2S administered and type of vessels involved; In the nervous system, H2S mediates 
neurotransmission12 and induces both neuroprotection and neurotoxicity 13, 14.  
 Under physiological conditions, H2S is present in plasma and organ systems as ~14% 
H2S, 86% HS- and a trace of S2- 15-17. Since these species coexist in aqueous solution together, 
it is difficult to identify the biologically active species that underlies the effects observed. 
Hence, the terminology -“H2S”- refers to the sum of H2S, HS- and S2-in the context of this 
thesis unless otherwise specified. NaHS or Na2S (or their hydrous forms) are most commonly 
used as an exogenous source of H2S. In aqueous solution, both release a rapid bolus of H2S 
which triggers downstream mechanisms. More recently, slow-releasing H2S compounds have 
been developed18-22 to mimick its physiological release. The clinical and pharmacological 
applications of these H2S donors hold promise as potential therapeutic treatment against a 
variety of disease conditions.  




1.2 Biochemistry of H2S 
1.2.1 Physical and Chemical properties 
 H2S is a colorless, flammable and water-soluble gas with a strong characteristic of 
rotten egg smell. In water, H2S is a weak acid which dissociates to form H+, HS- and S2- 23. At 
pH 7.4, about one third of “H2S” exists as the dissolved gas, H2S, while the other two thirds 
are HS- plus a trace of S2-. This was calculated from the pKa1 of 7.05 for the reaction H2S ↔ 
H+ + HS- value at 25oC in pure water 24. At mammalian body temperature of 37oC, the pKa1 
for H2S ↔ H + + HS- is 6.76 15 in water and 6.6 in 140mM NaCl 25. For pKa1 = 6.6, the 
Henderson-Hasselbach equation predicts that if H2S gas, or HS- (e.g. NaHS), or S2- (e.g. Na2S) 
is dissolved in an aqueous 140 mM NaCl solution at 37oC and pH 7.4, 14% of the free sulfide 
will be H2S gas and 86% will be HS-, plus a trace of  S2-. There is only a trace of S2- because 
pKa2 is greater than 12 15-17. Since all 3 species of sulfide are always present in aqueous 
solutions, it has not been possible to determine which of these species is biologically active. 
Thus the terminology of “H2S concentration” usually refers to the sum of H2S, HS- and S2-, 
although “sulfide concentration” is more accurate. In the context of this thesis, we follow the 
common convention of calling the sum of all free sulfide species “H2S concentration”.  
 One important property of H2S gas is that it is highly lipophilic. In fact, it is five times 
more soluble in lipids than in water, thus easily partitions into the hydrophobic core of the 
cell membrane and rapidly diffuses into or out of cells 26. Furthermore, H2S gas is very 
volatile. It may rapidly diffuse out of blood into lungs 27, or out of organ baths or cell culture 
media into air.  For example, when a 2 mm deep pool of culture medium containing 100 µM 
NaHS (i.e. ca. 14 µM H2S gas and 86 µM HS-) was exposed to air, the concentration of H2S 
(H2S + HS-) decayed exponentially with a half time of about 6 min as H2S gas escaped into 
the air 28. As H2S escaped, H+ in the buffered medium quickly combined with HS- to keep the 




H2S concentration at 14% in accordance with the pKa for H2S ↔ HS- of 6.6 in 140 mM NaCl 
at 37oC 25. This is an important point to note especially for in vitro experiments. 
1.2.2 H2S as a toxic gas 
 H2S has long been known as a toxic gas with the characteristic smell of rotten eggs. It 
is an environmental pollutant commonly present in industrial air and water pollution, derived 
mainly from industrial activities, such as paper pulp mills, petroleum refinery and urban 
sewers. Many reports of fatal intoxication by H2S have been documented 29-31.   
 At concentrations above 50 ppm, H2S irritates the eyes and respiratory tract, and mice 
breathing 80 ppm H2S at low environmental temperature go into a reversible hibernation-like 
state with reduced metabolism and breathing rate 32. This effect is species-dependent, as 80 
ppm H2S has no effect on 6 kg piglets 33, while 100 ppm kills canaries and guinea pigs 23. At 
concentrations above 500 ppm, H2S may cause unconsciousness and death in humans 23. H2S 
intoxication is often attributed to its potent, reversible inhibition of cytochrome c oxidase, 
thus blocking oxidative phosphorylation 23, 34, 35. Inhibition of other enzymes, such as 
carbonic anhydrase 36, monoamine oxidase 37, Na+/K+-ATPase and cholinesterase 23, also 
contributes towards its toxicity.  
1.2.3 Physiological level of H2S concentration 
 H2S-induced toxicity occurs at high concentrations of H2S levels. When physiological 
presence of H2S was revealed, a lot of research efforts have been invested to quantify for its 
physiological levels. Numerous earlier studies reported H2S to be above 35 µM 6, 38-40. In 
recent years, this earlier consensus has been challenged, mainly because fresh blood and 
tissues are odorless, but the same concentration of H2S in buffered salt solution emits very 
strong odor. It is now generally understood that majority of endogenously generated H2S may 




be stored on proteins, and only be released upon physiological stimulus 41. As such, free H2S 
concentration in blood and tissues was shown to be ~14 nM, determined by gas 
chromatography 42 or polarographic sensor 25, 43.  
 
Figure 1.1 Dissociation of H2S, and its various storage forms in proteins (Source: Self drawn) 
 The great disparity in reported H2S concentration in the past and present is due to the 
different H2S detection methods employed 43-48. Earlier publications which reported H2S 
concentrations above 35 µM in fresh blood or plasma 6, 49, 50 have employed either strong acid 
or strong base in their H2S detection methods, both of which causes sulfide release from 
sulfur-bound proteins 25. For example, the utilization of strong acid in the methylene blue 




method releases sulfides from acid-labile sulfur 25, 41. On the other hand, the strong base 
contained in the antioxidant buffer (utilized in sulfide-sensitive electrode detection method) 
releases protein bound sulfide and may cause protein desulfuration (releasing sulfide from the 
constituent cysteine and methionine) 25, 51. As such, the concentration of sulfide measured 
using these earlier methods is an overestimate of free sulfide concentration. Exclusion of 
strong acid or base in recent H2S measurement (gas chromatography and polarographic 
sensor) has led to a significantly lowered range of free sulfides detected.  
 
Figure 1.2 H2S concentration detection methods  
(Source: Self drawn, Published in Liu et al 52) 
 
1.2.4 H2S concentration in tissues or microenvironments 
 Although concentration of free H2S in body fluids may be low, its concentration in 
micro-environments may be high, especially in tissues or intracellular locations where H2S 




synthesizing enzymes are highly concentrated. For example, Levitt et al. have shown that free 
H2S concentration in freshly homogenized mouse aorta is 20 to 200 times more concentrated 
than in various other tissues they measured with the same method 46, probably due to the 
higher concentration of CSE in arteries.  
 Moreover, under the right physiological conditions or upon physiologic stimuli, free 
H2S may be released from sulfur stores to raise free H2S concentration in a micro-
environment 41. In rat brain, for example, it has been demonstrated that bound sulfur can be 
released as free sulfide from astrocytes when nearby neurons are active, thus raising 
extracellular K+, which activates the Na+/HCO3- cotransporter and alkalinizes the astrocytes, 
which together with the reducing activity of the glutathione (GSH) and cysteine normally 
present, causes the release of bound H2S 41. The brain has been reported to contain 61 µM 
“bound sulfur” 53. H2S released from stored sulfide as described above in the brain can act as 
a modulator of synaptic activity 12. Possible mechanisms similar to those described in the 
brain by Ishigami et al. 41 may occur in other organs or tissues.  
 Physiological mechanisms, as yet poorly understood, may add to or remove sulfide 
carried on plasma proteins. This may explain why the methylene blue and sulfide-sensitive 
electrode methods have shown that H2S in plasma increases or decreases in some human 
diseases or animal disease models, and that inhibitors of H2S synthesizing enzymes in animal 
models cause the measured plasma H2S (i.e. stored sulfide) to decrease, while also changing 
physiological parameters such as blood pressure (BP) in parallel. Experiments demonstrating 
physiological effects of higher concentrations of H2S than occur in mammalian macro-
environments may be uncovering effects of H2S concentrations that occur physiologically in 
micro-environments near reservoirs of sulfide bound to proteins or near high concentrations 
of CSE 52. Development of microelectrodes that are specific for detecting H2S or HS- may 
someday reveal such H2S “hot spots”.  




1.2.5 H2S as a gasotransmitter 
 The physiologic importance of H2S was only brought to our awareness in 1996 when 
Abe and Kimura groundbreakingly reported that H2S may act as a novel neuromodulator 12. 
Today, in less than two decades, a myriad of physiological and pathological relevance of H2S 
has been discovered.  
 H2S regulates heart contractile function and may serve as a cardioprotectant for 
treating ischemic heart diseases and heart failure. Alterations in endogenous H2S level have 
been found in animal models with various pathological conditions such as myocardial 
ischemia, spontaneous hypertension, and hypoxic pulmonary hypertension.  
 In vascular system, H2S exerts biphasic regulation of vascular tone with varying 
effects based on its concentration and the presence of nitric oxide. H2S has been found to 
promote angiogenesis and to protect against atherosclerosis and hypertension, while excess 
H2S may promote inflammation in septic or hemorrhagic shock.  
 In the central nervous system, H2S facilitates long-term potentiation and regulates 
intracellular calcium concentration in brain cells. H2S produces antioxidant, anti-
inflammatory, and anti-apoptotic effects that may be of relevance to neurodegenerative 
disorders. Abnormal generation and metabolism of H2S have been reported in the 
pathogenesis of ischemic stroke, Alzheimer’s disease, Parkinson’s disease, and recurrent 
febrile seizure. Exogenously applied H2S has been demonstrated to be valuable in the 
treatment against febrile seizure and Parkinson’s disease.  
 H2S has also been found to regulate the physiological and pathological functions of 
kidney, pancreas and bone.  Exogenously applied H2S may protect against ischemic kidney 
injuries and osteoporosis.   




 The molecular mechanisms underlying the biological actions of H2S have remained 
elusive. A recent article suggests that H2S is capable of S-sulfhydrating proteins by 
converting cysteine-SH groups to –SSH 54. This S-sulfhydration occurs in many different 
proteins due to the action of endogenously produced H2S, and it results in modifying the 
physiological functions of the proteins. Thus post-translational modification by H2S such as 
S-sulfhydration may be an important and key signaling mechanism underlying its diverse 
effects on various system 54.  Several molecules have been proposed as the potential targets of 
H2S action, inclusive of adenonsine triphosphate (ATP)-sensitive potassium channels (KATP) 6, 
adenylyl cyclase (AC) 12, 55, mitogen-activated protein kinases (MAPKs) 56 and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) 19, 57. 
1.2.6 Endogenous synthesis of H2S 
Free and bound sulfide originates from the action of enzymes that synthesize H2S. The 
four most important mammalian enzymes which synthesize H2S are: cystathionine β-synthase 
(CBS, EC 4.2.1.22), cystathionine γ-lyase (cystathionase, CSE, EC 4.4.1.1) and cysteine 
aminotransferase (CAT, EC 2.6.1.3) in conjunction with mercaptopyruvate sulfurtransferase 
(3-MST, EC 2.8.1.2).  
 





Figure 1.3 Biosynthesis of H2S in mammals  
(Source: Self drawn, published in Liu et al52) 
 
 Expressions of CBS and CSE have been detected in a broad variety of cell types, 
including liver, kidney, heart, vasculature, brain, skin fibroblasts, and lymphocytes. In some 
tissues, both CBS and CSE contribute to the local generation of H2S (such as in liver and 
kidneys) 58 whereas in others, one enzyme predominates.  
 For example, CSE is the main H2S-generating enzyme in the cardiovascular system 6, 
59. CSE-/- mice were reported to develop hypertension spontaneously 7, however a later study 
failed to reproduce this finding 60. Nevertheless, the significance of CSE in the cardiovascular 
system should not be disregarded as CSE-/- mice developed lethal myopathy and were 
susceptible to oxidative injury due to cysteine-diet deficiency 60.  
It was conventionally regarded that CBS is the predominant H2S synthase in the brain 
and nervous system 12. Recently, Shibuya et al. discovered that brain homogenates of CBS-/- 
mice produce H2S at levels similar to those of wild-type mice 61. They demonstrated that 3-
MST is expressed in neurons of the brain. Along with CAT, 3-MST produces H2S using both 




L-cysteine and α-ketoglutarate as substrates. Their experiments suggest that 3-MST and CAT 
contribute to H2S formation in both the brain (201) and in vascular endothelium 61-63. 
However, CAT and 3-MST was reported to produce H2S only in alkaline conditions and in 
the presence of DTT, a strong reducing agent 64. Therefore, the physiologic relevance of 3-
MST as a source of H2S formation in brain remains to be elucidated in the future.  
On a side note, Stearcy and Lee demonstrated reduction of exogenous S8 to produce 
H2S by human erythrocytes using reducing equivalents from glucose oxidation 65. They also 
found a slower production of H2S without adding S8, suggesting an endogenous source of 
sulfur in red blood cells 65. Inorganic synthesis of H2S may thus contribute towards 
endogenous H2S formation in vivo though its implication is yet to be discovered.   
1.2.7 Catabolism of H2S 
 The vast majority of H2S is oxidized to sulfate which leaves the body via the kidneys 
42, 66-68. The primary site for this oxidation is in the liver, but all cells in the body can oxidize 
H2S 25, 42, 67, even plasma and blood. It has been suggested that a major portion of the ability 
of plasma or blood to rapidly consume sulfide added in vitro is due to binding of the sulfide 
to proteins 66.   
 Endogenous H2S may be metabolized in vivo via different routes. As a readily 
diffusible gas, it can be metabolized in mitochondria by oxidation to thiosulfate which is 
further converted to sulfite and sulfate by sulfate oxidase 67. Finally, the end-products, 
sulfates, are excreted in urine as either free or conjugated sulfate 35, 66. Another metabolic 
pathway involves the methylation of sulfide by cytosolic S-methyltransferase to methanethiol 
and dimethylsulfide 67. H2S can also be scavenged by methemoglobin 35 or metallo- or 
disulfide-containing molecules such as oxidized glutathione 69. Hemoglobin may act as a 
common sink for vasoactive gases (CO, NO and H2S) and these three gases compete with 




oxygen for binding, thus contributing to their toxicity upon high exposure.  
 
Figure 1.4 Catabolism of H2S in mammals  
(Source: Self drawn, published in Liu et al52) 
 
Mammalian lungs may occasionally provide an escape route for H2S, possibly during 
septic shock, hemorrhagic shock, or pancreatitis when larger than normal amounts of H2S 
may be generated. In healthy individuals, however, very little H2S is lost via the lungs 
because metabolic disposal keeps the free level of H2S in blood very low 42. End expiration 
normally contains only 25-50 ppb H2S 70, 71 in healthy subjects, thus the normal daily loss of 
H2S via the lungs is negligible compared to the loss of sulfate in urine. 





Figure 1.5 Origins (green arrow) and disposal routes (red arrows) of H2S  
(Source: Self drawn, published in Liu et al52) 
 




1.2.8 Interaction with other gasotransmitters  
 Under physiological conditions, gaseous mediators (i.e. H2S, NO and CO) might be 
present at the same time, and accumulating evidence now suggests that interaction among 
gaseous mediators may influence or alter overall biological effects, in contrast to their 
individual effects 72-76. Interaction between H2S and NO may also regulate heart function. 
Yong et al. first reported that a mixture of NO donor and H2S produces positive isotropic 
effect in the heart whereas H2S and NO alone produces opposite effect. The effect of 
interaction could be abolished by thiols, suggesting that a new molecule that is thiol sensitive 
could have been formed. Nitroxyl (HNO) was proposed to be the product 77 due to the strong 
reducing capability of H2S 78-80 and the structural and pharmacological similarities with HNO 
77. The formation of HNO as an end-product of H2S and SNP interaction was further 
supported by Filipovic et al under physiological cellular conditions and in isolated mouse 
heart81. Filipovic et al proposed that the interaction is independent of NO released from SNP, 
but rather a direct effect between H2S and SNP. This is in contrast with Yong et al’s 
observations in which various types of NO donors such as L-arginine (NOS substrate) or 
DEANO were used and similar effect to that of SNP was found 77, 82. Nevertheless, the 
formation of HNO as a result of H2S and NO or SNP interaction warrants further in depth 
studies to be fully resolved. 
 In the vascular system, interaction between NO and H2S is controversial. Hosoki et al 
first reported that NO and H2S act synergistically in vasorelaxation5.  On the contrary, later 
studies reported that H2S pretreatment inhibited SNP-induced vasorelaxation10. Ali et al. 
showed that mixing NO donors (SNP, SIN-1 or SNAP) with NaHS (100 µM) reduced the 
extent of vasorelaxation compared to the relaxation with NO donors alone, further indicating 
inactivation of NO by H2S 3. The authors ascribed these observations to formation of a 




nitrosothiol compound 3, which is still unidentified till date. It is highly likely that this new 
compound is HNO, as mentioned above, instead of a nitrosothiol77, 81, 82.  
 Experiments carried out in liver suggest that CBS may act as an in vivo CO sensor 73, 
83. It has also been observed that CBS activity can be directly inhibited by NO and CO 84. 
More work has to be done to unveil any possible physiological roles of such interactions.  
1.3 Physiological functions of H2S in the cardiovascular system   
1.3.1 Effect of H2S on heart function  
H2S may markedly reduce action potential duration (APD) and decelerate sinus 
rhythm, while having no significant effect on the amplitude of action potential and resting 
potential85. HERG/Ikr and KvLQT1/Iks are two important potassium channels that control 
APD. Till date, H2S has not been reported to affect the function of these channels in the heart. 
Therefore, the effect of H2S on APD is probably attributed to the opening of KATP channels86. 
H2S is capable of opening KATP channels directly87, 88. Furthermore, H2S may also activate 
KATP channels indirectly by inducing intracellular acidosis89-92 and  other potassium 
channels93. However, the involvement of these channel activations towards shortening of 
APD is yet to be clearly understood and warrants further research.  
H2S produces negative inotropic effect in rat hearts. In isolated rat ventricular 
myocytes, H2S decreased the amplitudes of myocyte twitch and electrically-induced calcium 
transients upon stimulation of β1-adrenergic receptors with isoproterenol94. Using isolated 
heart, perfusion with H2S inhibited maximal/minimal left ventricular pressure development  
(±LVdp/dtmax)95. H2S perfusion in vivo via femoral vein produced a similar effect on the 
cardiodynamics of anesthetized rats 95. However, H2S at concentration up to 100 µM NaHS 
had no significant effect on heart rate in isolated rat hearts96, 97. 




 Different mechanisms have been implicated in the inhibitory effect of H2S on heart 
contractility. Firstly, H2S opens KATP channels. Secondly, H2S may inhibit AC/cAMP 
pathway to suppress β-adrenoceptor system, thereby producing negative inotropic effects94. 
Thirdly, H2S reduces peak current of L-type Ca2+ channels (LTCC; ICa, L) which is important 
in controlling heart contractility and cardiac rhythm85. The inhibitory effect of H2S on LTCC 
may be secondary to other signaling pathways, such as hyperpolarization caused by opening 
of KATP channels87, 88 or the suppression of cAMP/PKA pathway94, since H2S opens LTCC 
channels in various brain cell types28, 98, 99. 
 
Figure 1.6 Effect of H2S on electrophysiology of heart  








1.3.2 Effect of H2S on heart diseases  
Under ischemic conditions, endogenous H2S production in the heart is 
lowered27,39,64,67,68, along with downregulated CSE activity 100 and mRNA gene expression49. 
Treatment of ventricular myocytes with ischemic solution reduced endogenous H2S level59. 
In animal studies, rats injected with isoproterenol to produce “infarct-like” myocardial 
necrosis were found to have lowered H2S levels in myocardium101 and reduction in plasma 
H2S level by 66%102. Consistent with these, a clinical observational study showed that plasma 
H2S concentration in patients with coronary diseases is significantly lowered compared with 
control subjects (26 µM vs 52 µM), suggesting that the decreased plasma H2S levels may 
correlate with severity of coronary diseases103. These observations suggest that plasma H2S 
level has the potential to be used as a biomarker for ischemic heart diseases.  
 In view that the lowered H2S may be the cause of ischemia-induced damage or 
arrhythmias, exogenous H2S has been administered in various heart disease models to study if 
it induce any protective effects, and will be discussed in the following sections.     
1.3.2.1 Effect of H2S on ischemic heart diseases  
 Exogenously applied H2S was found to reduce myocardial infarction size in rats1, 49, 
104, mice2 and pigs105-107. Treatment with H2S significantly protected heart against 
ischemia/reperfusion (I/R)-induced arrhythmias 59, 108 and improved myocardial contractile 
function in ISO-induced ischemic rat heart102 and I/R-induced ischemic porcine heart107. 
Inhibition of endogenous H2S production significantly increased infarct size109, 110, whereas 
stimulation of endogenously produced H2S by overexpression of CSE reduced infarct size 2.  
H2S was found to inhibit the progression of apoptosis after I/R injury. H2S treatment 
suppressed activation of caspase-3, poly (ADP-ribose) polymerase (PARP) and terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive nuclei in mice2  and 




swine107. It also suppressed the expression of pro-apoptotic proteins via caspase-independent 
cell death through phosphorylation of glycogen synthase kinase-3 (GSK-3β)105. Yao et al. 
also demonstrated that H2S increased phosphorylation of GSK-3β (Ser9) and thus inhibited 
the opening of mPTP111. H2S also improved cardiac ATP pools112 and reduced mitochondrial 
oxygen consumption2. It preserves mitochondrial function by increasing complex I and II 
efficiency113, inhibiting respiration and limiting ROS generation2. Therefore, the 
cardioprotective effects of H2S involve its anti-oxidative function112, 114. 
 Anti-inflammatory effect of H2S may contribute to its cardioprotection.  H2S 
decreased the number of leukocytes within the ischemic zone by inhibiting leukocyte-
endothelial cell interactions2. It also decreased myocardial IL-1β 2, TNF-α, IL-6 and IL-8 
levels 106. Therefore, inhibition of leukocyte transmigration and inhibition of cytokine release 
are possible mechanisms for H2S-induced anti-inflammatory and cardioprotective effects. 
Other cardioprotective mechanisms of H2S may include suppression of β-adrenergic function 
94, inhibition of Na+/H+ exchanger (NHE) activity 115, opening of KATP channels 1 and 
blockade of LTCC 85, attenuation of endoplasmic reticulum (ER) stress116 and preservation of 
endothelial function 112.  
H2S treatment I/R protocol Species/tissue Effects of NaHS Mechanism Ref 
H2S administration 
NaHS (0.1µM & 1µM perfusion 10 
min prior to LAD occlusion till 10 
min reperfusion 
I (30 min)/ 
R (120 min) 
Rats/ Langendorff 
heart, MI (↓) KATP channel 
1 
NaHS (40 µM) throughout the 
experiment 
I (40 min)/ 
R (120 min) 
Rats/ Langendorff 
heart, MI (↔)  
 
110 
PAG I (40 min)/ R (120 min) 
Rats/ Langendorff 
heart, MI (↑) 
NaHS (40 µM) perfusion during  
reperfusion 
I (30 min)/ 






KATP channel 108 
NaHS (14 µmol/kg/day) i.p. from 





Rats/ in vivo MI (↓), mortality (↓)  49 
NaHS (0.1, 1, 10 µmol/kg/day) i.p. 




Rats/ in vivo 
MI (↓), internal diameter 
(↓), Anterior wall 
thickness (↑)  
 104 
NaHS (10-500 µg/kg) administered 
into LV lumen at the time of 
reperfusion; CSE overexpression 
I (30 min)/ 
R (24 h) 
Male C57BL6/J 




MI (↓), apoptosis (↓), 
inflammation  (↓)  
Preserve mitochondrial 
function, improve 
recovery of respiration 
rate, anti-apoptosis , 
Anti-inflammation 
2 
Bolus: NaHS (0.2 mg/kg)  over 10 
Sec at the onset of ischemia; 
Infusion: NaHS (2 mg/kg/h) during 
I/R period 
I (60 min)/ 
R (120 min) Swine/ in vivo 
Bolus: no effect 
Infusion: MI (↓),  
Hsp27, αB-crystallin, 
phosphor-glcogen 
synthase kinase-3 β, 
anti-apoptosis 
105 
Na2S: bolus (NaHS, 100 I (60 min)/ Swine/ in vivo MI (↓), improve Anti-inflammation 106 




Table 1.1 Effect of exogenous H2S against myocardial ischemia-reperfusion damages 
(Source: Self drawn, published in Liu et al52) 
 H2S preconditioning (SPreC) produces cardioprotective effects 59, 104, 117-121. 
Interestingly, SPreC produces stronger effect than post-ischemic H2S treatment 104. The 
protective effects of direct H2S treatment may rely mainly  on the ability of sulfide to reduce 
inflammatory responses 122 and to neutralize cytotoxic ROS such as peroxynitrite (ONOO-) 123, 
which may relieve oxidative stress partly, but not enough to salvage infarcted myocardium. 
SPreC is more likely to protect the heart by switching it to a defensive mode against ischemic 
insults. SPreC may trigger a series of signaling proteins including opening KATP channels117, 
activation of Protein Kinase C (PKC, especially ε-isoform)118, ERK1/2-MAPK120 and 
PI3K/Akt pathways120. By activation of pro-survival pathways, SPreC may stimulate cells to 
counteract stressful conditions. These pathways result in the production of various molecules 
(e.g. HSPs, GSH, and bilirubin) endowed with antioxidant and antiapoptotic activities 121. 
SPreC also activates signal transducer and activator of transcription (STAT)-3, which 
prevents cleavage of caspase-3, inhibits translocation of cytochrome C and reduces the 
number of TUNEL-positive nuclei 121. The anti-apoptotic actions are found to be, at least 
partially, mediated by inhibition of pro-apoptotic factor Bad, upregulation of pro-survival 
factors Bcl-2 and Bcl-xL, and an upregulation of HSPs.  
In addition, COX-2/PGE2 pathway 114, 119, prevention of intracellular calcium 
overload and hypercontracture118, NO117 and nuclear factor-erythroid-derived 2 (NF-E2) 
related factor 2 (Nrf2)/anti-oxidative stress121 have all been implicated in SPreC-induced 
cardioprotection52. These results suggest that H2S therapy may enhance endogenous 
ug/kg)+infusin (NaHS, 1 mg/kg) R (120 min) contractile function and 
coronary microvascular 
reactivity 
NaHS: 100 µM perfusion 10 min 
before and during ischemia in the 
isolated heart 
I (30 min)/ 




function and increase cell 
viability 
Inhibition of NHE 115 
Na2S: 10 min prior to and throught 
reperfusion 
I (60 min)/ 
R (120 min) Swine/ in vivo MI (↓) Anti-apoptosis 
107 
NaHS: 3 mg/kg, i.v. I (25 min)/ R (120 min) Rat/ in vivo MI (↓) KATP 109 
PAG: 50 mg/kg, i.v. I (15 min)/ R (120 min) Rat/ in vivo MI (↑) 




antioxidant defense of myocytes and create an environmental resistance to the oxidative 
stress associated with myocardial I/R injury, as evidenced by the preservation of redox state 
and a reduction in lipid peroxidation.  
Table 1.2 Effect of H2S preconditioning against myocardial ischemia-reperfusion damages 
(Source: Self drawn, published in Liu et al52) 
 
1.3.2.2 Effects of H2S on heart failure (HF)  
Myocardial infarction (MI) is the leading cause of HF. Plasma H2S level was found to 
be decreased in both MI124 and arteriovenous fistula (AVF)-induced congestive HF (CHF) 
models 125, 126.  In addition, endogenous H2S synthesis in the heart was also found to be 
lowered in adriamycin -induced cardiomyopathy model 127. Further evidence from transgenic 
mice overexpressing CSE resulting in excessive H2S production was shown to offer 
protection against CHF injuries in both permanent left coronary artery (LCA) ligation model 
as well as LCA I/R model 128.  
Cardiac hypertrophy as a result of sustained overload can lead to progression of HF. 
H2S pretreatment prevented cardiomyocyte hypertrophy by lowering intracellular ROS, 
upregulating microRNA-133a and suppressing microRNA-21 in rat primary cultures129. 
H2S treatment I/R protocol Species/tissue Effects of NaHS Mechanism Ref 
H2S Preconditioning 
Late: After preconditioning with 
NaHS (100 µM) for 30 min , cells 
were cultured in normal medium for 
20 h 
I (5 min)/ 
R (10 min) 
Rats/ 
cardiomyocytes 
Cell viability  (↑), LDH 
(↓), improvement of 
calcium handling 
KATP, NO 117 
Early: 3 cycles (NaHS 100 µM for 3 
min each cycle separated by 5 min of 
recovery) 
I (30 min)/ 




viability  (↑),improvement 
of [Ca2+]i handling 
KATP 59 
Late: After preconditioning with 
NaHS (100 µM) for 30 min, cells 
were cultured in normal medium for 
20 h 
I (5 min)/ 
R (10 min) 
Rats/ 
cardiomyocytes 
Cell viability  (↑), LDH 
(↓), improvement of 
contractile function 
COX-2/ PGE2 119 
Late: After preconditioning with 
NaHS (100 µM) for 30 min, cells 
were cultured in normal medium for 
20 h 
I (5 min)/ 
R (10 min) 
Rats/ 
cardiomyocytes 
Cell viability  (↑), 
improvement of [Ca2+]i 
handling 
PKC 118 
Early: 3 cycles (NaHS 100 µM for 3 
min each cycle separated by 5 min of 
recovery) 
I (35 min)/ 





viability  (↑),improvement 
of contractile function 
ERK, Akt 120 
Late: NaHS (0.1-1 µmol/kg i.p.) 1, 3 
or 5 day before MI Permanent MI 
Rats/ 
in vivo MI (↓) PKC 
104 
Early: Na2S (100 µg/kg i.v.) 30 min or 
2 h before MI 
I (45 min)/ 
R (24 h) 
Mice/ 
in vivo MI (↓) 
Early: Antioxidant 
(Nrf2), PKCε, STAT-3 
121 Late: Na2S (100 µg/kg i.v.) 1 day 
before MI 
Late: Antioxidants 








Overexpression of CSE reduces left ventricle dilation and cardiac hypertrophy128. Exogenous 
application of H2S attenuated the development of hypertrophy in spontaneously hypertensive 
rats (SHR)130.  Exogenously applied H2S was shown to attenuate development of adriamycin-
induced cardiomyopathy127.  
Anti-oxidative effect of H2S is probably the main mechanism for its therapeutic effect 
on CHF known to date. Application with H2S inhibited lipid hydroperoxidation (LPO) and 
increased activities of superoxide dismutase (SOD) and GSH peroxidase. Therefore, 
treatment with H2S stimulates the activity of anti-oxidant enzymes 131. H2S may reduce LPO 
and protect heart against HF injury via stimulation of Akt and nuclear localization of NRF-1 
and Nrf2 128. H2S also decreased the number of apoptotic cells through promoting the 
expression of anti-apoptotic factor Bcl-2 while suppressing expressions of pro-apoptotic 
factors Bax and caspase-3. The release of cytochrome c from mitochondria was reduced. 
These anti-apoptotic effects therefore mediated the cardioprotective effects of H2S124. 




























NA Transgenic mice displayed:  
-68% ↑ in survival rate 
-smaller ↑ in LVEDD, 
LVESD and heart to body 
weight ratio 
CSE overexpression 
reduced LV dilatation 
and cardiac hypertrophy 
Transgenic mice 
hearts expressed:  





60 minutes of 
LCA 
occlusion 
followed by 4 
weeks of 
reperfusion 
Transgenic mice displayed: 
-38% ↓ in infarct area 
-Smaller ↑ in LVEDD, 
LVESD, and heart to body 
weight ratio  
-better LV ejection fraction 
↑ production of H2S 
during reperfusion has 
positive impact on LV 
structure and function 






24 hour reperfusion: 
-14% ↓ in infarct area/area at 
risk  
-20% ↓ in infarct area/LV 
4 weeks reperfusion: 
-25% ↓ in infarct area/LV 
-No change in LVEDD, 
LVESD, heart:body weight 
ratio, LV ejection 
fraction, or heart rate 
Single administration 
of H2S at reperfusion 
improves infarct size, but 
not sufficient to improve 
LV function at 4 weeks 
-↑ nuclear 
localization of Nrf2 
and NRF-1  
-↑ Akt 
phosphorylation  in 





respiration and ATP 
synthesis, but no 
effect on  
mitochondrial 
biogenesis 
Na2S (100  
µg/kg, i.v) 
during first 
7 days of 
reperfusion 
Na2S treatment:  
-25% ↓ in infarct area,  
-↓ in LV dilatation and 
cardiac hypertrophy 
-improved cardiac function 
H2S during first 7 days 
of reperfusion is critical 
for sustained 
improvements in LV 








-↓ heart weight 
-↓ collagen, ↓ fibrosis 
H2S  
-↓ oxidative and 
proteolytic stresses 











water -↓ caspase-3 and apoptosis  
-↓ nitrotyrosine formation 
-↓ MMP-9 and MMP-2 
activation 
-↑ TIMP-4, ↓ TIMP-1 and 
TIMP-3  
-↑ β1-integrin, ↓ADAM -12 
- improved cardiac 
histology by ↓ fibrosis 
and apoptosis 
expression of 











-↓ in LV chamber diameters 
-restored hemodynamics 
parameters of heart- EF, 
EDP, ESP, dP/dt max and SV 
-↑ expression of MMP-2, 
CD31 and VEGF 




-↓ dilatation of heart 































-↑ survival rate by 15% 
-↑ LVSP 
-↓ LVEDP 
-↑ LV ±dp/dt  
-↓ lung:body weight ratio 
-↓ fibrosis area/ total LV area 
-↑ CSE, Bcl-2 expression 
-↓ Bax expression 
-↓ mitochondrial:cytoplasm 






-↓ pulmonary oedema 
-↓ fibrosis 
-↓ cardiac apoptosis 
 








-↑ Bcl-2 protein and 
mRNA expression 
-↓ Bax and caspase-

















H2S restored  
-LVESP, LV dP/dt and 
PRSW  
- sensitivity of coronary 
arteries to acetylcholine-
induced vasorelaxation 
H2S improves  
-ventricular function 
-endothelial recovery 










Table 1.3 H2S effects against various heart failure models (Source: Self-drawn) 
1.3.3 Effect of H2S on blood vessels  
 The effect of H2S on vascular tissues was first reported by Hosoki et al. in 1997, 
which discovered that both arteries and veins express CSE and generate H2S 5. NaHS at 
concentrations above 100 µM may induce relaxation of precontracted isolated rat artery 3, 5, 6. 
Furthermore, perfusion of the rat mesenteric arterial bed with the H2S precursor increased 
endogenous release of H2S and relaxed the arterial bed 4.  In contrast, NaHS at concentrations 
below 100 µM may induce further contraction of precontracted isolated vessels 3, 11, 133. The 
response of blood vessels to H2S varies according to the type of vessel: large conductance 
vessels vs small resistance vessels; systemic vs pulmonary; the condition of endothelium 
(intact vs denuded); the precontraction agonist used (e.g. potassium chloride vs 
phenylephrine); the method of H2S administration (single vs cumulative application), and the 
duration, concentration, and rate of change in concentration of the H2S administered. 




H2S induced vasodilation has been reported  in thoracic aorta, mesenteric arteries, 
pulmonary artery, tail artery and other types of vascular tissues 5, 6. H2S-induced 
vasorelaxation is mainly underlied by opening of KATP channels 4, 6, 134 and partially mediated 
by endothelium-dependent mechanism(s)6. Other signaling mechanisms involved includes 
intracellular acidosis92 depletion of intracellular ATP levels8, 9, 80 and elevations in cyclic 
guanosine monophosphate (cGMP)/PKG135. More recent studies refer H2S as an endothelium 
derived hyperpolarizing factor (EDHF)136. This is supported by findings that IKCa/ SKCa 
channels underlie H2S effect, and IKCa, but not KATP and BKCa channels, mediate H2S-
induced hyperpolarization in cultured human aortic ECs136. Taken together, these studies are 
suggestive that H2S play important roles in mediating vascular responses of small and 
intermediate resistance vessels. H2S-induced vasoconstrictive effects are also mediated by 
multiple mechanisms. It has been found that H2S may reduce NO synthesis in endothelium 134, 
or interact with NO to form a nitrosothiol compound, which itself has no effect on vascular 
activity3. However, H2S-induced vasocontriction is not completely abolished in the presence 
of NOS inhibitor or removal of endothelium, suggesting that other NO-independent 
mechanisms might be implicated.  One possibility is the downregulation of cAMP level in 
VSMCs11, which then upregulates the activation of myosin light chain kinase to induce 
vasoconstriction.  
 





Figure 1.7 Mechanisms of H2S-induced vascular responses  
(Source: Self drawn, published in Liu et al52) 
 
 




1.3.4 Effect of H2S on vascular proliferation and angiogenesis 
Current evidence suggests that H2S promotes angiogenesis and cell growth. H2S 
enhances cell migration, growth and proliferation in endothelial cells 137 138. Under hypoxic 
conditions, H2S-induced angiogenesis is probably HIF-1α/VEGF-dependent  139.  
H2S also promotes vascular network formation under pathological situations. A 
hindlimb ischemic model was established in rats that were subjected to unilateral femoral 
artery ligation. NaHS at 50 µmol/kg/day, but not (200 µmol/kg/day), promoted collateral 
vessel growth in ischemic hindlimbs, along with increased regional blood flow and increased 
capillary density 140. This implies that H2S may promote vascular network formation in vivo 
at near physiological concentration. The signaling mechanisms for the angiogenic effect of 
H2S involve activation of Akt 137, MAPK/ERK kinase (MEK)138 and Hsp27 138.  
 
Figure 1.8 Mechanisms of H2S-induced angiogensis  
(Source: Self drawn, published in Liu et al52) 
 




1.3.5 Effect of H2S on vascular disease 
The concentration of H2S in blood has been reported to be altered in several pathological 
states, including patients suffering from coronary artery disease (CAD) 103 , hypertension 45 
and diabetes 141. Although these changes in H2S levels reflect changes in the amounts of 
stored sulfide (due to the methods used to measure blood concentrations), the H2S 
concentrations of stored sulfide probably reflect the status of H2S activity. Whether such 
changes in H2S level are the causes or consequences of these diseases warrants further 
investigations.    
1.3.5.1 Effect of H2S on atherosclerosis  
H2S level were found to be significantly reduced in either vascular beds or plasma 
during the development of atherosclerosis. This is probably due to the inhibition of CSE 
expression and activity142, 143.  In apoE-/- mice, plasma H2S and aortic H2S synthesis were also 
decreased. However, CSE mRNA in aorta was found to be elevated, probably due to the 
existence of a positive compensatory feedback mechanism144.  
Exogenously administered H2S suppressed the development of neointima hyperplasia 
142,  decreased vascular calcium content, calcium overload  and alkaline phosphatase activity 
in calcified vessels 143 and reduced atherosclerotic plaque size and improved aortic 
ultrastructure 144. The anti-atheroscerotic effects involve anti-inflammatory 144 and anti-
apoptotic 145 effects on smooth muscle cells, cytoprotective effects in endothelial cellss 146 
and inhibition of LDL modifications and oxidation 146, 147.  





Figure 1.9 Mechanisms of H2S-induced atherosclerosis  
(Source: Self drawn, published in Liu et al52) 
 
1.3.5.2 Effects of H2S on hypertension  
The role of endogenous H2S in blood pressure regulation is still controversial. 
Pharmacological blockade of endogenous H2S production with hydroxylamine hydrochloride, 
a non-specific inhibitor of both CSE and CBS, for four weeks failed to influence SBP in rats 
148. In contrast, Yan et al. found that administration of PAG, an inhibitor of CSE, to rats for 
five weeks significantly elevated blood pressure149. The discrepancy was also observed in 
CSE-knockout mice. Yong  et al reported these mice exhibit pronounced hypertension 7, 
whereas Ishii et al. did not found hypertension in these mice 60.   
Plasma level of H2S and the expression of CSE mRNA was significantly lowered in 
SHR 149 and hypoxic pulmonary hypertensive rats 150. These findings suggest that the 
hypertension in SHR involves a reduction in the production and function of H2S 149.  




Treatment with H2S can significantly lower BP in different hypertensive animal 
models include SHR 149, renovascular hypertension 148 and pulmonary hypertension 150.  The 
mechanism for the anti-hypertensive effects involve inhibition of the renin-angiotensin 
system (RAS) 151, attenuation  of vascular remodeling 152 and activation of KATP channels 18.  
1.4 Clinical Significance of H2S 
Unveiling the protective effects of H2S in preclinical studies has implicated H2S as a 
potential treatment or therapy under pathophysiologcal conditions. In recent years, H2S or 
H2S donors have been used in clinical trials involving human subjects in various studies.  
IK-1001 is a liquid formulation of Na2S that has been developed to deliver H2S in an 
injectable form. The use of this donor has been tested in a large-animal model using male 
pigs, as well as in clinical trials among human volunteers. In a Phase I randomized, single-
blind, placebo-controlled, dose escalation study consisting of 36 healthy volunteers, a single 
injection of IK-1001 showed no adverse effects or laboratory clinical abnormalities at the 
various doses tested (0.005, 0.01, 0.03, 0.06 and 0.1 mg/kg). In another study, administration 
of IK-1001 (0.005–0.20 mg/kg intravenously, infused over 1 min) induced an increase in 
blood sulfide and thiosulfate concentrations over baseline. In all subjects, basal exhaled H2S 
was observed to be higher than the ambient H2S concentration in room air, indicative of 
spontaneous endogenous H2S production in human subjects. Upon intravenous administration 
of IK-1001, a rapid elevation of exhaled H2S concentrations was observed, which is 
reversible after infusion is stopped. Hence, exhalation is one of the routes of elimination of 
IK-100170 [83].  
At present, no human trial has been conducted to study the effects of H2S on renal 
ischemia because this is still relatively a new niche in comparison with the well-established 
cardiovascular and CNS protective effects of H2S. Nevertheless, a Phase I clinical trial was 
executed to study the pharmacokinetics of IK-1001 in healthy volunteers, as well as subjects 




with varying degrees of impaired renal function following a single intravenous infusion 
(ClinicalTrials.gov ID: NCT00879645) [101] . The safety and efficacy of IK-1001 against 
I/R-mediated cardiac tissue injury was determined in a Phase II clinical trial involving 
patients who were undergoing coronary artery bypass graft (ClinicalTrials.gov ID: 
NCT00858936) [101]. In a separate Phase II study, the safety and efficacy of IK-1001 was 
investigated in reducing the severity of damage done to the heart during ST-segment ele-
vation myocardial infarction surgery (ClinicalTrials.gov ID: NCT01007461) [101].  
Furthermore, the H2S level was speculated to play an important role during acute 
pancreatitis. Its upregulation during the inflammatory process and whether its levels of 
elevation predict disease severity are assessed using blood samples of such patients 
(ClinicalTrials.gov ID: NCT00786591) [101]. H2S levels are also tested as a prognostic factor 
of mortality and severity of shock in patients admitted into an intensive care unit owing to 
shock of any reason (defined as systemic arterial pressure lower than 90 mmHg or drop of 
systemic arterial pressure of at least 40 mmHg for 15 min or more with elevation of serum 
lactate value) (ClinicalTrials.gov ID: NCT01088490) [101].  
In addition, there have been a lot of ongoing or completed trial projects studying the 
effects of garlic or garlic extracts among human volunteers and patients. The findings of 
these studies might shed light on the effects of H2S, as H2S might be involved in the 









1.5 Research rationale and objectives 
1.5.1 Background and epidemiology 
Cardiovascular diseases (CVD) are the leading cause of death in the world. In 2004, it 
accounts for 32% of all deaths in women and 27% in men. By 2030, it was projected be the 
leading cause of death attributing to 23.6 million deaths each year. 
 
Figure 1.10 Projected deaths by cause and income 
(Source: Global Burden of Disease, World Health Organization) 
 
Hypertrophy refers to the compensatory mechanism of the heart in an effort to 
respond to the sustained increase in hemodynamic load. The outcome of sustained 
overloading will eventually result in heart failure (HF). HF refers to the physiological state of 
the body in which cardiac output is insufficient in meeting needs of the body. It affects 5.2 
million Americans with over 400,000 new cases being diagnosed each year. In Singapore, 
77,000 people (2% of the population) are plagued by the disease.  
The existing treatment for HF includes cardiac glycosides (e.g. ouabain, digitalis and 
digoxin) 153. However, despite their efficacy in improving cardiac function directly, they 
produce severe toxic effects such as cardiac arrhythmias, disturbances of atrio-ventricular 
conduction, gastrointestinal disorders, neurological effects, anorexia, blurred vision, nausea 
and vomiting. Toxicity can be induced by drug-interactions or the patient’s physiological 




condition. Henceforth, the narrow therapeutic range of cardiac glycosides limits their clinical 
uses.  
Another type of effective treatment against HF produces therapeutic effects by 
pharmacologic blockade of renin-angiotensin system (RAS). Renin is the first and rate 
limiting enzyme of RAS, catalyzing the cleavage of angiotensinogen to form angiotensin I 
(Ang I). Under the action of angiotensin converting enzyme (ACE), Ang I is further 
converted to angiotensin II (Ang II). The latter is a powerful vasopressor and a stimulator of 
aldosterone secretion. Excessive activity of the RAS can result in hypertension, disorders of 
fluid and electrolyte homeostasis and deterioration of cardiac tissue damage. The existing HF 
therapies utilize ACE inhibitors or angiotensin receptor blockers. They act by decreasing 
preload and/or afterload of the heart via dilatation of vascular tone, inhibition of cardiac 
oxygen consumption and reduction in blood volume.  
 
Figure 1.11 Compensatory mechanisms for role of RAS in HF (Source: internet) 
However, renin may produce tissue damage independent of Ang II. Activation of the 
(pro)renin receptor has been shown to stimulate blood pressure elevation and target organ 
damage 154-161. Clinical findings also showed that high renin levels correlates with 
pathological progresses such as left ventricular hypertrophy 162, 163 and severe intrarenal 
vascular damage. A recent study by Fisher et al. further shows that aliskiren, a renin inhibitor, 
produces stronger and longer renal vasodilation response than that observed with ACE 




inhibitors (ACE-Is) or Ang II receptor blockers (ARBs) 164, suggesting that inhibition of renin 
may provide more beneficial effects than ACE-Is and ARBs.  
For the last decades, scientists have therefore been exploring new drugs acting on 
renin production or (pro)renin-receptors. The first renin inhibitor, aliskiren, was approved by 
the Food and Drug Administration for use in the United States in March 2007. Aliskiren 
binds to the active site of renin and prevents the binding of angiotensinogen. However, the 
bioavailability of aliskiren is poor. As such, there is a growing need for development of new 
drugs to inhibit renin and prevent heart failure developments.  
1.5.2 Literature review and gap in knowledge   
Over the past two years, scientists have begun to study the protective effects of H2S 
against heart failure in vivo. Five papers have been published thus far. Despite the disparity in 
animal model used and H2S dosing regimen, all papers unanimously suggested the promising 
cardioprotective effects of H2S. All papers suggested that H2S treatment could improve 
cardiac function and hemodynamic factors. The protective effects of H2S are in agreement 
with previous literatures using in vitro studies as well as other in vivo models (table 1.3). 
However, the suggested mechanism of actions varies drastically.  
Works by Calvert et al. is the most informative and comprehensive. They used both 
CSE overexpression transgenic mice as well as exogenous H2S administration to confirm that 
H2S acts to increase Akt phosphorylation in heart at serine residue 473. Furthermore, they 
showed that H2S increased nuclear localization of two transcription factors-nuclear 
respiratory factor 1 (NRF-1) and nuclear factor-E2-related factor (Nrf2). These collectively 
increase the levels of endogenous antioxidants, attenuate apoptosis and increase 
mitochondrial biogenesis. 
Mishra et al. and Givvimani et al. are two papers published by the same laboratory- 
the former utilized a volume overload model 126whereas the latter used a pressure overload 




model132. Both papers adopted the same H2S administration regimen and worked on the same 
animal species. Both papers obtained very similar results and suggested the same mechanism 
of action. They proposed that H2S reversed the alteration of various matrix 
metalloproteinases (MMP) and tissue inhibitor of matrix metalloproteinases (TIMP) in 
response to cardiac insults, and these factors resulted in enhanced angiogensis in H2S treated 
animals. It is intriguing that NaHS produce such potent effect via drinking water as H2S is 
known to have very short half-lives and escapes readily into air within minutes. Furthermore, 
NaHS at 30 mol/l produces strong irritating odor and its dissociation ions (HS- or S2-) may 
change the taste of water. Water intake by H2S treated animals may differ drastically as 
compared to other groups and care should be taken when we analyze these data.   
Wang et al. reported that H2S may exert its protective roles by inhibiting apoptosis. 
These data are in line with H2S effects seen in atherosclerosis models published previously 145, 
165, 166. The last article by Szabo et al. utilized 20 dogs and proposed that the effects of H2S is 
mediated by  improving endothelial recovery and preservation of ATP pools. However, their 
conclusion is based solely on the contractility of coronary artery in response to acetylcholine. 
This single experiment is insufficient to arrive at their proposed conclusion.       
The vast differences in proposed mechanisms underlying effects of H2S are strongly 
suggestive of the lack of understanding of H2S action. Inhibition of RAS has been implicated 
in prevention of HF. In fact, ACE inhibitors and angiotensin receptor blockers have long been 
utilized as effective therapies to prevent HF development in patients subsequent to their 
myocardial infarction attack. Despite the well-established association between RAS and heart 
failure, no study has yet been published to study the effect of H2S on RAS components in HF 
model animals.  
Conventionally, renin is believed to be produced by juxtaglomerular (JG) apparatus of 
the kidney, and activated renin will be released into the circulation under conditions of 




intravascular volume contraction, reduced arterial pressure and hypokalemia. Renin in the 
systemic circulation then act on angiotensinogen produced from liver to generate Ang I, 
which is later converted into Ang II catalyzed by ACE in the pulmonary circulation. 
Accumulating evidence now supports the existence of a local RAS axis in the myocardium, 
and Ang II level at tissue level is independent of circulating RAS. This hypothesis is built 
upon observations that: 
1. RAS components including Ang II, renin, ACE, angiotensionogen and angiotensin 
receptors are present within the myocardium   
2. RAS is activated in myocardium of hypertrophied and failing heart 
3. Pharmacological blockade of RAS is effective therapy against animal models and 
patients with cardiac hypertrophy and failure  
As such, there is reason to believe that RAS play important role in mediating the 
transition from compensatory hypertrophy to HF. The existing literatures failed to explore the 
protective effects of H2S against HF in relation to alterations in RAS, hence the gap of 
knowledge in the present study.   
1.5.3 Specific Aims 
Renin is the enzyme acting on the rate-limiting step to produce Ang II, a powerful 
vasopressor and a stimulator of aldosterone secretion. Thus, inhibition of renin release could 
be an important therapeutic target for the treatment of HF. H2S has potent vasodilation effect 
and has been shown to lower blood pressure in hypertensive animals7. As renin release and 
RAS has been implicated in hypertension and HF, we hypothesize that H2S may be a 
potential therapy by lowering renin and suppressing. The present proposal is designed to 
investigate the action mechanisms for the therapeutic effects of H2S on cardiac myopathy. 
Specifically, we will 
1. Investigate effect of H2S in lowering renin in renin-dependent renal hypertension  




2. Determine underlying mechanisms of H2S inhibition on renin release in renin-rich 
granular cells of juxtaglomerular (JG) apparatus  
3. Investigate therapeutic effects of H2S on renin/Ang II-induced heart pathological 
condition 









Chapter 2. H2S lowers blood pressure of renal hypertensive rats by 
inhibiting plasma renin activity (PRA) 
2.1 Introduction 
The development of renovascular hypertension depends on the release of renin from 
the juxtaglomerular (JG) cells, a process regulated by intracellular cAMP. Hydrogen sulfide 
(H2S) downregulates cAMP production in some cell types by inhibiting adenylyl cyclase, 
suggesting the possibility that it may modulate renin release. Here, we investigated the effect 
of H2S on plasma renin activity and blood pressure in rat models of renovascular 
hypertension.  
2.2 Methods and Materials 
2.2.1 Renal hypertension animal models 
Seven-week-old male Sprague–Dawley (SD) rats were anesthetized with ketamine 
(75 mg/kg, intraperitoneally) and xylazine (10 mg/kg, intraperitoneally). In the 2-kidneys-1-
Clip (2K1C) and 2K1C+NaHS groups, the left kidney was exposed through a lumbar incision 
and the left renal artery was dissected free and clipped by a rigid U-shaped silver clip with a 
0.25-mm slit. The sham procedure was performed including the entire surgery, with the 
exception of arterial clipping. The rats were kept in cages after surgery with constant 
temperature (25°C) and humidity. They were exposed to a 12:12-hour light-dark cycle and 
had unrestricted access to tap water and food.  
2.2.2 Experimental Protocol 
NaHS [0.56, 1.68, and 5.6 mg/kg per day (or 10, 30, 100 μmol/kg per day)] was 
administered daily to rats via intraperitoneal injection starting from day 3 after surgery in the 
2K1C+NaHS group, and NaHS (5.6 mg/kg per d) was applied in the 2K1C+NaHS group. 




Sham and 2K1C control rats received vehicle (saline) treatment. To examine the therapeutic 
effect of H2S after development of renovascular hypertension, NaHS (5.6 mg/kg per d) was 
given 8 days after surgery. To investigate the effect of H2S on BP in normal rats, NaHS (5.6 
mg/kg per d) was applied daily to normal rats via intraperitoneal injection.  
2.2.3 Blood Pressure (BP) measurement 
Systolic BP was measured in calm, conscious rats using a tail-cuff transducer 
connected to Powerlab system running Chart5 software (Powerlab, AD Instruments). SBP 
was measured in each rat immediately before and weekly after surgery for the following 4 
weeks across all groups. SBP of normal rats was tested before treatment to determine the 
baseline and once a week after treatment for 4 weeks. Before each measurement, the rats 
were prewarmed to 35°C for 10 minutes in a cupboard. The average of three pressure 
readings was recorded for each measurement. After 4 weeks, SBP and diastolic BP (DBP) 
were recorded at the right carotid artery with a catheter (PE-50) connected with a transducer 
and Powerlab system. Animals were anesthetized with ketamine (75 mg/kg, intraperitoneally) 
and xylazine (10 mg/kg, intraperitoneally). Powerlab system software automatically 
calculated mean arterial pressure.  
2.2.4 Renin Assay 
Renin activity was measured at the National University Hospital of Singapore by 
radioactive immunoassay with quantitative determination of angiotensin I. Briefly, blood 
samples or culture medium (preincubated with excess renin substrate) were collected by 
centrifuging at 2000 × g for 10 minutes. A five-hundred-microliter sample of supernatant, 10 
μl of phenylmethylsulfonyl fluoride, and 50 μl of angiotensin I generation buffer were added 
into noncoated generation tubes to generate angiotensin I. After incubation for 90 minutes at 
37°C, the generation tubes were immediately placed in an ice bath. The following assay was 




performed at room temperature. Fifty microliters of sample or calibrator and 500 μl of tracers 
were added to the bottom of tubes that were coated with the 125I-labeled hormone, BSA, 
phosphate buffer, stabilizers, preservatives, and an inert red dye. Radioactivity was 81 kBq 
(2.2 μCi). The contents of tubes were mixed with a vortex and incubated for 3 hours at room 
temperature. The incubation mixture was carefully aspirated and a Gamma counter suitable 
for counting 125I measured the radioactivity of tubes (counter window setting, 15 to 80 keV; 
counter efficiency, 70%; counting time, 1 minute). PRA was calculated as nanograms 
angiotensin I generated per milliliter per hour [PRA = (ng 37°C − ng 4°C) × 1.12/h of 
incubation].  
2.2.5 ACE Assay 
A fluorescence-based protocol was used to quantify ACE activity167. Briefly, tissue 
samples (50µl) were mixed with 150µU ACE substrate working solution (Sigma, A-6778) 
and 0.45 mM O-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (200 µl, Bachem, E-
2920) in a 96-well microplate and incubated at 37°C for 30 minutes. The fluorescence signals 
before and after 30-minute incubation were obtained using a microplate fluorometer (Thermo 
Electron) at excitation and emission wavelengths of 365 and 415 nm, respectively. The 
differences in fluorescence signals between 0 and 30 minutes were used to represent ACE 
activity. 
2.2.6 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
RT-PCR analysis was performed by LightCycler (Roche Diagnostics). Gene 
expression was normalized to the endogenous control glyceraldehyde-3-phosphate 
dehydrogenase mRNA in each sample. The following primers were used: for renin, sense 5’- 
CCCCTGTCTTTGACCACAT-3’ and antisense 3’-CGCACAGCCTTCTTCACAT-5’; for 
glyceraldehyde-3-phosphate dehydrogenase, sense 5’-TGAACGGGAAGCTCACTGG-3’ 
and antisense 5’-TCCACCACCCTGTTGCTGTA-3’. RT-PCR was performed at 50°C for 30 




minutes and at 95°C for 15 minutes for RT, followed by 30 cycles of PCR reaction consisting 
of 94°C (45 seconds) for denaturation, 58°C (45 seconds) (or 52°C for renin) for annealing, 
and 72°C (45 seconds) for extension. A final extension was performed at 72°C for 10 minutes. 
Afterwards the PCR products were separated by electrophoresis on a 1.5% agarose gel. 
2.2.7 Western Blot 
Tissue samples were homogenized in tissue lysis buffer (1:10, w/v; Sigma). Protein 
concentrations were determined by the Lowry method. Protein samples (30 µg) were 
separated by 10% SDS/PAGE and transferred onto a nitrocellulose membrane (Amersham 
Biosciences). After blocking at room temperature in 10% milk with TBST buffer (10mM 
Tris-HCl, 120Mm NaCl, 0.1% Tween-20, pH 7.4) for 1 hour, the membrane was incubated 
with renin (1:500, AnaSpec) and β-actin (1:1000, Santacruz) primary antibodies at 4°C 
overnight. Membranes were then washed 3 times in TBST buffer, followed by incubation 
with 1:10,000 dilutions of horseradish-peroxidase-conjugated anti-rabbit IgG at room 
temperature for 1 hour and washing 3 times in TBST. Visualization was carried out using an 
ECL (advanced chemiluminescence) kit (GE Healthcare). The density of the bands on 
Western blots was quantified by densitometry analysis of the scanned blots using 
ImageQuant software. 
2.2.8 Statistical Analysis 
All data are presented as mean ± SEM. Statistical significance was assessed with one-
way ANOVA followed by a post hoc (Tukey) test for multiple group comparison. 
Differences with P < 0.05 were considered statistically significant. 






2.3.1 H2S reversed BP elevation in 2K1C-renovascular hypertensive rats 
To examine the preventative effect of H2S on the development of renovascular 
hypertension in 2K1C rats, sodium hydrosulfide (NaHS; an H2S donor) was given daily from 
day 3 after surgery until the end of the 4-week experiment in the 2K1C+NaHS group.  
Figure 2.1 shows that SBP in 2K1C rats was significantly elevated starting from the 
first week after surgery, and it continued to rise during the entire 4 weeks of observation. 
Treatment with NaHS (5.6 mg/kg per day, intra-peritoneal) attenuated the development of 
hypertension starting from the second week to the end of fourth week.  
 
Figure 2.1 Time-course of renovascular hypertension development in the presence and 
absence of NaHS (5.6 mg/kg per day, intraperitoneal) treatment.  (n =7-8) Data are expressed 
as mean ± SEM. #P < 0.05, ##P < 0.01, and ###P <0.001 versus respective values in sham 
rats. *P < 0.05 and **P < 0.01 versus respective values in 2K1C rats.  
 
A dose-dependent effect of NaHS was investigated. Our results showed that at 1.68 to 
5.6 mg/kg per day (30 to 100µmol/kg per day), NaHS significantly reduced BP elevations 
after 4 weeks of treatment (Figure 2.2). 
 
 





Figure 2.2 Antihypertensive effect of NaHS at different doses (0.56, 1.68, and 5.6 mg/kg per 
day). BP was measured at the end of the 4-week treatment (n = 5-10). Data are expressed as 
mean ± SEM. ###P <0.001 versus respective values in sham rats. *P < 0.05 and **P < 0.01 
versus respective values in 2K1C rats.  
 
To confirm the antihypertensive effect of NaHS, the right carotid artery was 
catheterized to monitor BP at the end of 4 weeks. As shown in Table 2.1, systolic, diastolic, 
and mean artery pressures were all significantly elevated in 2K1C rats compared with those 
in sham-operated rats. NaHS treatment attenuated the elevation of BP in all of these 
parameters. This is consistent with the data measured with the non-invasive tail-cuff system 
(Figure 2.1). Taken together, these data clearly suggest that NaHS treatment produces 
significant anti-renovascular hypertensive effects. 
 
Table 2.1 Effect of NaHS treatment on body weight and carotid BP in 2K1C rats 
2.3.2 Effect of NaHS on RAS in 2K1C rats 
 To understand the antihypertensive effects of NaHS, we investigated the involvement 
of RAS. As shown in Figure 2.3, PRA was significantly elevated to 71.9 ± 12.3 ng/ml/hour in 
the plasma of 2K1C rats, which was approximately 5-fold of that in the sham rat (14.0 ± 2.7 




ng/ml/hour). NaHS treatment dramatically reversed the elevated PRA to 26.1 ± 10.1 
ng/ml/hour.  
 
Figure 2.3 Treatment with NaHS (5.6 mg/kg/day, i.p) for 4 weeks abolished the elevation of 
PRA in 2K1C rats. n=5-6. ### p<0.001 vs sham, ** p<0.01 vs 2K1C   
We next examined the effect of NaHS on ACE activity. Incubation of normal rat 
aortic tissue with NaHS (1 - 1000 µmol/L) for 30 min failed to affect ACE activity. In 
contrast, captopril (1 µmol/L), an ACE inhibitor, abolished ACE activity in the aorta (Figure 
2.4). 
 
Figure 2.4 Acute effects of NaHS (1-1000 µmol/L, 30 min) on ACE activity in normal rats. 
Captopril (1 µmol/L) was used as a positive control. ### p<0.001 vs control. n=5-7. 
ACE activity in the aortic tissues was markedly elevated in 2K1C rats compared to 
that in sham rats (Figure 2.5). The observation is consistent with the previous reports 168-171. 
Neither chronic treatment with NaHS (5.6 mg/kg/day) for 4 weeks, nor acute treatment with 




NaHS (10-1000 µmol/L) for 30 min, influenced the upregulated ACE activity in 2K1C rats. 
However, captopril (1 µmol/L) abolished the ACE activity in aortic tissues.  
 
Figure 2.5 Acute (30 min, 10-1000 µmol/L) and chronic (4 weeks, 5.6 mg/kg/day) treatment 
with NaHS on ACE activity in rat aorta of 2K1C rats.  Captopril (1 µmol/L) was used as a 
positive control. ### p<0.001 vs sham, ** p<0.01 vs 2K1C control. n=5-7. 
The plasma level of Ang II was also investigated. As shown in Figure 2.6, Ang II 
level was elevated to 42.6±12.9 pg/ml in the plasma of 2K1C rat, which was approximately 
5-fold of sham operated rat (8.4±3.7 pg/ml). Treatment with NaHS for 4 weeks reduced Ang 
II level to 14.0±3.3 pg/ml. 
 
Figure 2.6 NaHS (5.6 mg/kg/day) treatment for 4 weeks significantly reduced the elevated 








2.3.3 Effect of NaHS on protein level of renin in 2K1C rats 
We further examined the renin level in the kidneys using western blotting. Renin 
protein level was significantly increased in the clipped (Figure 2.7A), but not in the unclipped 
(Figure 2.7B) kidney of 2K1C rats. NaHS treatment for 4 weeks significantly attenuated the 
elevated renin protein level in the clipped kidney (Figure 2.7A).  
 
Figure 2.7 Effect of NaHS on the protein of renin in the kidneys of 2K1C rats. NaHS 
treatment inhibited the upregulated renin expression in clipped kidney (A), but had no action 
on unchanged renin level in unclipped kidney (B). n=5. ### p<0.001 vs sham, ** p<0.01 vs 
2K1C. 
 
2.3.4 Effect of NaHS on mRNA level of renin in 2K1C rats 
We also examined the effect of NaHS on the mRNA level of renin in the clipped 
kidneys of 2K1C rats. As shown in Figure 2.8, NaHS treatment markedly suppressed the 
upregulated renin mRNA level in the clipped kidney of 2K1C rats. Hence, our data suggest 
that H2S may inhibit renin synthesis.  





Figure 2.8 NaHS suppressed the upregulated renin mRNA level in clipped kidney of 2K1C 
rats. n=4. ## p<0.01 vs sham, * p<0.05 vs 2K1C. 
 
2.3.5 Effect of NaHS on cAMP level in the clipped and unclipped kidneys of 2K1C rats 
Among the intracellular signaling pathways involved in the regulation of renin 
secretion, the cAMP pathway signaling cascade is the central and stimulatory pathway for the 
exocytosis of renin. To examine the mechanism underlying H2S-suppressed PRA, we 
observed cAMP production in both clipped and unclipped kidney with and without NaHS 
treatment. As shown in Figure 2.9, cAMP was markedly elevated in 2K1C clipped kidney 
compared with that in either 2K1C unclipped kidney or the kidneys from sham rats. NaHS 
treatment for 4 weeks significantly inhibited the elevated cAMP levels in the clipped kidney 
in 2K1C rats.  
 
Figure 2.9 Effect of NaHS treatment (5.6 mg/kg/day) on cAMP production in both clipped 
and unclipped kidney in 2K1C rats. n=6-9. ## p<0.01 vs sham, *** p<0.001, * p<0.05 vs 2K1C 
clipped group 




2.3.6 Effect of NaHS on BP and renin activity in normal rats 
Systemic administration of NaHS or hydroxylamine hydrochloride (HA), an inhibitor 
of CSE and CBS, for 4 weeks had no significant effect on blood pressure and PRA in normal 
rats (Figure 2.10). Our data suggest that H2S may regulate PRA only when RAS is over 
activated.  
 
Figure 2.10 Effects of NaHS and HA on (A) blood pressure and (B) PRA in normal rats. Both 
NaHS and endogenous H2S failed to affect blood pressure (A, n=8) and PRA (B, n=5). 
 
2.4 Discussion  
The renin-angiotensinogen reaction is the first and rate-limiting step in the production 
of Ang II and thus could be a therapeutic target for treatment of hypertension. The most 
important finding in this study is that H2S inhibits PRA, thus producing therapeutic effects on 
renovascular hypertension in 2K1C rats.  
Using the 2K1C renovascular hypertensive model, we found that H2S may possess 
marked therapeutic value against hypertension induced by renal artery stenosis. The 
elevations of both systolic and diastolic BP were significantly attenuated by NaHS treatment 
for 4 weeks. All these beneficial effects of H2S are mostly attributed to the decreased PRA 
and Ang II production in plasma, hence our data suggest that H2S exerts antihypertensive role 
by suppressing the excessively activated RAS.  




We also examined the underlying mechanism for the inhibitory effect of H2S on PRA. 
Among the intracellular signaling pathways involved in the regulation of renin secretion, the 
cAMP pathway signaling cascade appears to be the central and stimulatory pathway for the 
exocytosis of renin 172. All maneuvers that increase cellular cAMP levels in JG cells, such as 
activation of AC, inhibition of cAMP-phosphodiesterases, and addition of membrane-cAMP 
analogs, stimulate renin secretion. We found in the present study that cAMP content in 
clipped kidney of 2K1C rat was much higher than unclipped one. The elevated cAMP level 
was down-regulated by NaHS treatment. 
The effect of NaHS on renin synthesis was measured by determining mRNA and 
protein levels of renin in the clipped kidney of 2K1C rats. It was found that systemic 
treatment with NaHS inhibited both the elevated mRNA and protein levels of renin in the 
clipped kidney tissues, suggesting that H2S may also inhibit renin synthesis.  
Both exogenous application of NaHS or suppression of endogenous H2S production 
failed to change BP and PRA in normal rats. This suggests that the anti-hypertensive effect of 
H2S is specific only to hypertension with higher PRA. This is also supported by our data that 
H2S only decreased the upregulated renin activity and renin protein in the clipped kidney in 
2K1C rats, but had no effect on normal renin protein level in the unclipped kidney in 2K1C 
rats.  
In conclusion, our findings suggest that H2S may potentially be a novel therapeutic 
approach for treatment against renovascular hypertension by suppressing excessively 
activated RAS. The mechanism of H2S-induced inhibition on renin release, however, 
warrants confirmation and further research efforts.   





Chapter 3. H2S inhibits renin release from renin-rich granular cells of Juxtaglomerular 
(JG) apparatus    
3.1 Introduction 
In the previous chapter, we found that H2S exerted inhibitory effect on plasma renin 
level and activity in a renin-dependent renovascular hypertension model. In this chapter, we 
aim to have a closer look at inhibitory effect of H2S on renin release at tissue level and 
cellular level to better understand the underlying mechanism of this phenomenon.   
The granular cells of JG apparatus are specialized smooth muscle cells present on the 
wall of the afferent arterioles of the kidney that synthesize, store and secrete renin. Renin 
release from renal granular cells upon stimulation will enter the systematic circulation and 
participate in blood pressure homeostasis. Renin secretion occurs in response to the following: 
1. Decreased blood pressure detected by baroreceptors 
2. Detection of low sodium concentration by the macula densa cells  
3. Stimulation by sympathetic nervous system  
 To study whether the antihypertensive effect of H2S is specific secondary to inhibition 
of renal renin release, we observed the venous PRA after acute renal stenosis for 30 min. We 
also further investigated the effect of H2S on renin release on isolated granular cells.    
3.2 Methods and Materials 
3.2.1 Acute low-renal-blood-flow experiment 
Male SD rats weighing 180g-250g were used and anesthetized with ketamine (75 
mg/Kg, i.p.) and xylazine (10 mg/kg, i.p.). Left kidney was exposed through an abdominal 
incision 1.5 cm below xiphoid process, and the left renal artery was cautiously dissected free 
from vein and avoid to dragging the blood vessel. The left kidney arteries were clipped with a 




rigid U-shaped silver clip with 0.25 mm slit for 30 min. NaHS (100 µM) or saline were 
perfused into right femoral vein by a butterfly needle (27 gauge, 0.4×10 mm) at a speed of 
400 µl/min 15 min before and during the whole process of artery occlusion. At the end of 30 
min occlusion, blood samples were collected from renal vein with a 27 gauge needle (0.4×12 
mm) for renin activity determination.  
3.2.2 Isolation of renal granular cells 
Male SD rats weighing 180g-250g were used and anesthetized with ketamine (75 
mg/Kg, i.p.) and xylazine (10 mg/kg, i.p.). Kidneys were aseptically removed, perfused with 
enzymes in Krebs buffer (mM) of 111 NaCl, 5.0 KCl, 1.0 NaH2PO4, 11.2 glucose, 25 
NaHCO3, 0.54 Mgcl2, 2.5 CaCl2, 0.1% bovine serum albumin, 0.1% collagenase (Type I; 
Sigma), 0.017 mg/ml DNase (Type IV; Sigma). The kidneys were then decapsulated and 
papilla removed. Each kidney was cut into longititudinal halves, followed by mincing 
cortices with a scalpel blade to obtain tissue pieces of about 1 mm3 size. The minced tissue 
was suspended and incubated in enzyme solution at 37℃ for 90 min and enzyme activity was 
terminated by dilution (1:10) with 20% fetal bovine serum. Suspension was filtered with a 
105 µm nylon mesh. Cell suspension was centrifuged at 250 g for 2 min and resuspended in a 
40% Percoll solution (Sigma) followed by ultracentrifugation at 29000 g for 20 min at 4℃. 
Typically, the cells were separated by density into several visible layers 173. A tube containing 
standard density beads (reconstituted according to directions from Pharmacia Fine Chemicals 
AB, Uppsala, Sweden) was also placed in the same rotor and spun simultaneously. The 
sedimentation density of individual cell layers was determined by comparison with the 
location of the colored density marker beads 173. The third band from top with a density of 
1.067g/mL was then harvested by aspiration. Cells were washed for three times with enzyme-
free Krebs Buffer to ensure cells were free from Percoll and then cultured in medium 
containing 10% fetal bovine serum. 




3.2.3 Immunofluorescent staining of granular cells 
To confirm the cells isolated from cell layer with density of 1.067 g/ml are renin-rich 
granular cells, immunofluorescent staining of cells with anti-renin antibody was carried out to 
test for presence of renin in cell layer 1.067 g/ml vs cell layer 1.033 g/ml. Cells were 
resuspended in 3.7% formaldehyde for fixation. After incubating for 10 min at room 
temperature, cells were diluted with PBS and spun down. Resuspended cells were 
permeabilized with 0.1% Triton X-100 for 2 min. Permeabilized cells were again diluted and 
spun down, and cell density counted. The fixed and permeabilized cells were loaded onto 
cytospin slides that were mounted with cuvettes and filter pads assembled in a metal rack, 
and centrifudged at 2000 rpm for 3 min (Thermo Scientific Cytospin 4 Cytocentrifuge). The 
slides were then dried and fixed before immunohistochemistry staining procedures were 
carried out. 
Figure 3.1 showed that strong red fluorescence was detected with anti-renin antibody 
in most cells in the cell layer with density of 1.067 g/ml (A), but not that in cells from 1.033 
g/ml (B). This indicates that cells from 1.067 g/ml cell layer are mostly granular cells which 
are rich in renin, and these cells are then utilized for subsequent experiments.  
 
 





Figure 3.1 Immunostaining of renin in rat kidney cells. Cells were isolated from the layer 
with cell density of 1.067 g/ml (A) and 1.033 g/ml (B). Intracellular renin granule (a) and cell 
nucleus (b) were stained with anti-renin (1:400; Anaspec) and DAPI (1:10,000). Merged 
images of both stainings are depicted in (c). Photos were taken at X40 magnification. 
3.2.4 Renin assay 
Renin activity was measured in National University Hospital (NUH) of Singapore 
with radioactive immunoassay by angiotensin Ⅰ radioimmunoassay kit. Briefly, cell medium 
or perfusate was kept at 4℃ in the EDTA coated tubes and collected by centrifuging at 2000 
X g for 10 min. Add 500 µl sample, 10 µl PMSF and 50 µl angiotensin I generation buffer 
(containing abundant amount of angiotensinogen, 4 ml citrate buffer solution, stabilizers, 
preservatives and an inert blue dye) into non-coated generation tubes to generate angiotensin 
I. After incubation for 90 min at 37℃, the generation tubes were immediately placed in an ice 
bath. The following assay was performed at room temperature. 50 µl of sample or calibrator 
and 500 µl of tracers were added to the bottom of tubes which were coated with the hormone 
labelled with 125I [radioactivity is 81 kBq (2.2 μCi)]. After mixing the contents of tubes with 
a vortex and incubating for 3 hours at room temperature, the incubation mixture was carefully 
aspirated and the radioactivity of tubes were measured by Gamma counter suitable for 
counting 125I (counter window setting: 15-80 keV - counter efficiency: 70% - counting time: 




1 min). Renin activity is calculated as ng angiotensin I generated/mL/hour (PRA = (ng 37°C - 
ng 4°C) x 1.12/ hours of incubation). 
3.2.5 cAMP assay 
To examine the involvement of cAMP, a direct cAMP enzyme immunoassay kit 
(Cayman Chemical, USA) was used 11, 94. Briefly, cells were incubated in Kreb’s solution 
containing different concentrations of NaHS (0.1-10 μmol/L) for 5 min, followed by 
application of forskolin (1 μmol/L), an AC activator, ISO (10 nmol/L), a β-adrenoceptor 
agonist, or 3-isobutyle-1-methylxanthine (IBMX, 100 μmol/L). After 15 min of incubation, 
cells were lysated in 0.1 mol/L HCl in ice for 20 min and then centrifuged at 1000 g for 10 
min. Trichloroacetic acid (TCA) was extracted from supernatant using water-saturated ether. 
50 µl of samples were added into 96-well plate followed by incubation with cAMP AchE 
tracer and cAMP antiserum for 18 h at 4℃. Samples were developed by Ellman’s reagent and 
read at wavelength of 405 nm.  
3.2.6 Statistical Analysis 
All data were presented as mean ± SEM. Statistical significance was assessed with 
one-way analysis of variance (ANOVA) followed by a post hoc (Tukey) test for multiple 
group comparison. Differences with p value less than 0.05 were considered statistically 
significant. 
3.3 Results 
3.3.1 H2S inhibited acute renal-artery-stenosis-induced venous PRA elevation  
Perfusion pressure to kidney is the most important regulator of renin release. Stenosis 
of renal artery decreases blood flow and glomerular filtration rate, followed by enhancing 
renin secretion. To confirm whether the anti-hypertensive effect of H2S is specific to the 




inhibition of renal renin release, instead of chronic effect on angiogenesis, we examined 
whether NaHS can regulate venous PRA induced by acutely decreasing blood supply. 
As shown in Figure 3.2, subsequent to 30 min of vessel occlusion, PRA in renal 
venous blood raised to 43.67 ± 4.87 ng/ml/hour, which was approximate 3-fold of that in 
control group (14.0 ± 2.7 ng/ml/hour). Intravenous injection of NaHS (40 nmol/min) 15 min 
before and during occlusion significantly attenuated the elevated PRA to 28.72 ± 3.99 
ng/ml/hour.  
 
Figure 3.2 Perfusion with NaHS (40 nmol/min) significantly inhibited the stenosis-stimulated 
venous PRA. n=9-10, ### p<0.001 vs control, * p<0.05 vs vehicle group. 
 
3.3.2 H2S inhibits renin release from renin-rich granular cells via lowering cAMP levels  
cAMP is the best-established second messenger responsible for regulating renin 
release in granular cells 174. All maneuvers that increase cellular cAMP levels in granular 
cells such as activation of adenylyl cyclase, inhibition of cAMP-phosphodiesterases or 
addition of membrane-cAMP analogs have been shown to stimulate renin secretion. To test 
whether H2S affects cAMP level in granular cells, we pre-incubate isolated granular cells 
with NaHS for 5 min before subjecting the cells to cAMP stimulation by forskolin (an 




adenylyl cyclase activator) or isoproterenol (ISO, a β-adrenergic receptor agonist) for another 
15 min. 
   
Figure 3.3 NaHS markedly suppressed (A) forskolin (1 µmol/L) and (B) ISO (1 µmol/L)-
stimulated cAMP in renin-rich granular cells. N=8-12. ##p<0.01 and ###p<0.001 vs control, 
and *p<0.05, **p<0.01 vs forskolin or ISO.  
 
3.3.3 H2S suppressed renin degranulation in granular cells  
  The effect of NaHS on renin degranulation in the renin-rich granular cells are then 
examined. As shown in figure 3.4A, NaHS attenuated ISO-induced renin-degranulation, 
indicated by reversal of ISO effects on intracellular renin protein level.  
 Since granular cells may produce both inactive and active renin, renin activity in 
culture medium of granular cells is measured. The level of angiotensin I, which was 
converted from angiotensinogen under the action of active renin, was measured as an 
indicator of renin activity. Treatment of cells with forskolin (figure 3.4B) or ISO (figure 
3.4C) markedly increased renin activity, whereas NaHS pretreatment reversed renin activity 
back to basal level (figure 3.4B-C). This suggests that NaHS may inhibit renin release from 
renin-rich granular cells.    
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Figure 3.4 Effect of NaHS on (A) renin protein level in ISO (1 µmol/L)-induced granular 
cells, and (B) forskolin (1 µmol/kg) or (C) ISO (1 µmol/L) –induced renin activity in cell 
culture medium. N=7-12. ##p<0.01 and ###p<0.001 vs control, and *p<0.05, **p<0.01 vs 
forskolin or ISO 
 
3.4 Discussion  
In this section, it was found that NaHS markedly inhibit renin release from granular 
cells of the kidney, demonstrated by renal stenosis and cellular evidences. Suppression of 
elevated cAMP level caused by stimulation of β-adrenoreceptors or adenylyl cyclase provides 
direct evidence to explain why H2S inhibited renin release. Inhibition of renin degranulation 
by H2S is clearly demonstrated by elevated renin protein content within ISO-induced cells, 
but decreased renin activity in culture medium. It is worthy to note that H2S pretreatment 
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alone without ISO or forskolin-stimulation has no significant effect on cAMP and renin 
levels. This implies that the mechanism of H2S action on cAMP and renin production lies 
with the synthesis of cAMP. Our findings may provide molecular evidence for the therapeutic 













Chatper 4. H2S prevents heart failure development via inhibition of renin 
release from mast cells in the isoproterenol (ISO) treated rats 
4.1 Introduction 
In addition to the classic circulating RAS, many tissues including the heart possess 
local RAS 175 which may exert autocrinic, paracrinic and/or intracrinic effects 176. It has been 
well accepted that local RAS contributes to the development of heart failure and LV 
remodelling via multiple mechanisms, including pathological extracellular matrix deposition, 
myocyte hypertrophy and pro-apoptotic effects175, 177-181.  
Mast cells, a multi-effector cell type best known for its roles in immediate 
hypersensitivity and chronic allergic reactions, are lately recognized as a local source of renin 
in cardiovascular tissues176, 182-184. Over the past decades, numerous reports have associated 
these cells with heart pathology, and they have been generally regarded as a harmful 
regulator in the heart. Mast cells have been associated with congestive heart failure in human 
patients 185 and myocardial infarction in a rat model 186. Zhang et al. showed that there is 
increased mast cell density during progressive myocardial fibrosis and diastolic cardiac 
dysfunction 187.    
Previously, H2S has been reported to protect against heart failure and prevent 
hypertrophy, probably via induction of anti-oxidative responses, inhibiting apoptosis and 
promoting angiogenesis52. We discussed in previous sections the therapeutic effects of H2S 
against renin-dependent hypertension via inhibition of renin synthesis and release (chapters 2 
and 3)148, 188. In the present chapter, we aim to elucidate whether H2S could prevent heart 
failure development via inhibition of local renin release from mast cells in cardiac tissues. 
 





4.2 Methods and Materials 
4.2.1 Drugs and chemicals 
NaHS, ISO and forskolin were purchased from Sigma-Aldrich (St. Louis, MO). All 
chemicals were dissolved in physiological saline (0.9%, Merck) under sterile conditions 
immediately before injections. NaHS was used as an H2S donor and was freshly prepared on 
the day of every experiment.  
4.2.2 Animals 
Female Sprague-Dawley rats aged 6–8 wk old (250–300 g) were obtained from 
Centre for Animal Resources. The animals were housed under diurnal lighting conditions and 
allowed to obtain food and water ad libitum. All experiments on animals were approved by 
Institutional Animal Care and Use Committee of National University of Singapore. 
4.2.3 ISO-induced cardiomyopathy as heart failure model and treatment protocol 
The disease model was established by toxic cardiomyopathy, which is the most 
widely used experimental model to study chronic heart failure 189. Excessive administration 
of catecholamines results in massive myocardial destruction and extensive fibrosis 190, and 
subcutaneous administration of ISO has been shown to induce infarct-like myocardial 
necrosis 101 and reduce functional capacity of the heart 191, 192. ISO-treated rats developed 
myocardial necrosis and progressive enlargement of the LV cavity out of proportion to mass, 
equivalent to humans with discrete myocardial infarction193, 194.  
Animals were randomly assigned to various treatment groups. All animals were 
injected either with NaHS of different dosage (0.056, 0.56 or 5.6 mg/kg/day, i.p.) or saline 
consecutively for three days before receiving one subcutaneous injection of 0 or 150 mg/kg 
ISO. The dosage of ISO administered was chosen based on previously published literature 
that 150 mg/kg ISO is the optimal dose to establish heart failure model195.  Subsequent to ISO 




injections, daily intraperitoneal NaHS or saline injections resumed until animals were 
sacrificed two weeks after ISO injections. 
4.2.4 Hemodynamics measurements 
Cardiodynamic parameters were measured with a pressure transducer connected to a 
PowerLab system (ADInstruments, Australia). Heart contractile function was in closed-chest 
spontaneously breathing rats anesthetized with ketamine (75 mg/kg) and xylazine (10 mg/kg). 
Left ventricle (LV) catheter was placed in the right carotid artery and advanced upstream into 
the LV. Left ventricular end diastolic pressure (LVeDP) was represented by the minimum 
pressure recorded during diastoles, left ventricular developed pressure (LVDP) was 
calculated as the difference between left ventricular systolic pressure and left ventricular 
diastolic pressure. 
To characterize contractile ability of the heart, contractility was represented by the 
maximum gradient during systoles (+dP/dt), whereas compliance was represented by the 
minimum gradient during diastoles (-dP/dt). 
4.2.5 Tissue Preparation 
Hearts were excised, rinsed with saline and blotted dry. Hearts were weighed and 
right ventricle was removed by dissection along its septal insertion. Weights of LV and 
thickness of LV were measured. Specimens were snap frozen in liquid nitrogen within 
minutes and stored at -80oC until analyzed.    
4.2.6 Biochemical studies 
Blood was collected via cardiac puncture for determination of lactate dehydrogenase 
(LDH) and PRA. Plasma LDH was determined using commercially available kit (Cayman 
Chemical) according to manufacturer’s instructions. Renin activity in plasma or LV 
homogenates was determined using renin activity assay (SensoLyte® 390 Renin Assay Kit, 
Anaspec)196. Procedures were carried out following manufacturer’s instructions with slight 




deviations. Briefly, renin substrate solution (component A) was added to 50 µl of each 
sample and fluorescence intensity was recorded at Ex/Em=330 nm/390 nm. Renin from 
samples cleaved Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptides to 
restore the fluorescence of Mc-Ala, which was otherwise quenched by Dnp. As such, 
fluorescence intensities recorded is directly proportional to renin activity in these samples, 
and this method has sensitivity of 8ng/ml for renin.  
4.2.7 Sirus red staining for collagen 
LV tissue was fixed in 10% formalin followed by dehydration and embedding in 
paraffin. Four-micrometer thick sections were cut and stained with Sirus red staining to stain 
for collagen deposition as described previously197, 198.  
4.2.8 Toluidine blue staining for mast cells 
Formalin-fixed LV tissues were paraffin embedded and four-micrometer thick 
sections were cut and stained with toluidine blue for mast cells. For each animal, mast cell 
count was determined by investigators who were blind to the treatment groups under 
microscope (Nikon Eclipse 80i, 400X). Tissue sections were sliced 3 mm above heart apex. 
Mast cell degranulation was defined as the presence of metachromatic granules close to the 
surface of the cell or staining of about half or less of the cytoplasm with toluidine blue as 
described previously199.  
4.2.9 Immunostaining for renin, mast cells and cell nuclei 
To visualize co-localization of renin and mast cells in tissue sections, sections were 
triple-stained with a rabbit polyclonal anti-renin antibody plus Alexa Fluor 594 donkey anti-
rabbit IgG for detecting  the renin expression, FITC-avidin for identifying mast cells and 
DAPI for visualizing nuclei as described previously176. Briefly, LV tissue sections were 
deparaffinizedin xylene and dehydrated in a gradient concentration of ethanol. Antigen 
retrieval was performed by microwave with citrate buffer (trisodium citrate 10 mM, 0.05% 




Tween 20, pH 6.0) for 20 minutes. Sections were rinsed in PBS and permeabilized for 10 
minutes at 37°C with a solution containing 4% FBS and 0.3% Triton X-100 dissolved in PBS. 
Next, 10% FBS was applied to the sections for 1.5 hours at 37°C prior to addition of 
antibodies. The polyclonal anti-renin antibody (1:400) was applied to the sections overnight 
at 4°C, followed by 3 washes in PBS. Next, sections were exposed to Alexa Fluor 594 
donkey anti-rabbit IgG (red; Invitrogen Corp) (1:1,100) and FITC-avidin (green) (1:1,300) 
for 1 hour at 37°C. Following 3 washes, the sections were incubated with a 1:10,000 dilution 
of DAPI (blue) for 3 minutes at room temperature. Sections were washed and then fixed for 3 
minutes with 4% paraformaldehyde. Finally, the sections were mounted in fluorescence 
mounting medium (Dako) and viewed under fluorescence microscope Nikon ECLIPSE 80i.  
We confirmed the presence and expression of renin in left ventricular tissue using 
fluorescent immunostaining (refer to figure 4.7), in line with previous observations 
reported182, 183. 
4.2.10 Leukotriene B4 and cAMP assays 
Leukotriene B4 and cAMP ELISA assay were carried out following manufacturer’s 
instructions using kits purchased from Cayman Chemicals (520111 and 581001, respectively). 
4.2.11 Western blotting 
LV tissue was homogenized in tissue lysis buffer. Protein concentrations were 
determined by the Lowry method. Protein samples (30 µg) were separated by 10% 
SDS/PAGE and transferred onto a nitrocellulose membrane (Amersham Biosciences). After 
blocking at room temperature in 10% milk with TBST buffer (10mMTris-HCl, 120mMNaCl, 
0.1% Tween-20, pH 7.4) for1 hour, the membrane was incubated with LTA4H and β-actin 
primary antibodies at 4°C overnight. Membranes were then washed 3 times in TBST buffer, 
followed by incubation with secondary antibody at room temperature for 1 hour and washing 
3 times in TBST. Visualization was carried out using an ECL (advanced chemiluminescence) 




kit (GE Healthcare). The density of the bands on Western blots was quantified by 
densitometry analysis of the scanned blots using ImageQuant software. 
4.2.12 Statistical analyses 
All data are expressed as means ± SEM. Statistical comparisons among different 
treatment groups were tested using one-way ANOVA followed by a post hoc analysis (LSD). 
Significance level was set at p<0.05 unless otherwise stated.  
 
4.3 Results 
4.3.1 Pretreatment with NaHS increased the survival rate in rats treated with ISO  
The first batch of 45 animals was used to select the dosage of H2S to be used in 
subsequent experiments. Subcutaneous injection of ISO (150mg/kg) resulted in massive 
deaths of animals due to the impairment of LV function as only two out of nine animals in 
ISO treated group survived the first three hours subsequent to ISO injection, equivalent to 
22.2% survival rate (Figure 4.1). No more deaths occurred beyond three hours. H2S 
administration consecutively for three days prior to ISO administration elevated survival rate 
to 6/9 (66.7% survival) in both 0.056 and 0.56 mg/kg/day NaHS treatment groups and 5/9 
(55.6% survival) in 5.6mg/kg NaHS group within the first three hours post-ISO injection. An 
additional death occurred within 12 h and 24 h post-ISO injection in 0.056 mg/kg (55.6% 
survival) and 5.6 mg/kg group (44.4% survival), respectively. These preliminary data suggest 
that NaHS treatment prior to ISO injection protected the heart against ISO-induced injury.  
However, H2S at high concentration (5.6 mg/kg/day) may induce toxicity52 which 
counteract its beneficial effects, evident from the lower survival rate than the lower doses 
(0.056 and 0.56 mg/kg/day). We then selected the lowest dose of NaHS for our subsequent 
experiments since there was no significant difference in survival rate among different dosages 
of NaHS administered.   





Figure 4.1. Effect of NaHS treatment on survival rate in rats received ISO injection. Massive 
deaths occurred within the first three hours subsequent to ISO injection, and pretreatment 
with NaHS at varying doses protected the heart against ISO-induced damages. n=9 in each 
group. 
4.3.2 Effect of H2S on somatic and organ weights in ISO-induced hypertrophy  
There was no significant difference in body weight (BW) at the end of two week follow-
up (Figure 4.2A) and BW change (ΔBW) (Figure 4.2B) throughout the course of study 
among different treatment groups. Heart weight (HW) and LV weight (LVW) were elevated 
in ISO treated group with p-values of 0.089 and 0.002 respectively (Figures 4.2C and E). 
When normalized with the body weights (BW) of these animals, HW/BW and LVW/BW 
were significantly increased in ISO treated group than sham controls (Figures 4.2D and F), 
suggesting that these animals developed hypertrophy subsequent to ISO injections.  
 





Figure 4.2. Effect of NaHS treatment on cardiac hypertrophy induced by ISO. A: Body 
weight (BW) at the end of two week follow-up; B:  Change in BW (ΔBW) through 2 weeks; 
C: Heart weight (HW); D: Ratio of HW to BW (HW/BW); E: Left ventricular weight (LVW); 
F: Ratio of LVW to BW (LVW/BW); n=5-16. Mean±S.E.M. * p<0.05, ** p<0.01, *** 
p<0.001 vs sham; # p<0.05 vs ISO. 
 
4.3.3 Effect of H2S on hemodynamic measurements 
Both DBP and SBP were significantly decreased by ISO administration. NaHS 
administration (0.056  mg/kg/day, i.p.) failed to significantly reverse the reduced DBP 
(Figure 4.3A ) and SBP (Figure 4.3B). ISO significantly altered LVDP (Figure 4.3C), LVeDP 
(Figure 4.3D) and ±dp/dt (Figure 4.3E-F). Treatment with NaHS in HF models attenuated 
alterations to these parameters, while NaHS alone had no significant effect on these 
hemodynamic factors when compared with sham group (Figure 4.3A–F). It is interesting to 
note that NaHS treatment only significantly improved heart function but not BP. This may be 




caused by the vasodilatory effect of NaHS, although only a slight decrease in BP was found 
in the normal rats treated with NaHS. Our data imply that NaHS may produce a stronger 








Figure 4.3 H2S treatment improved the impaired cardiac hemodynamics in ISO-induced heart 
failure rats. A: Diastolic blood pressure (DBP); B: Systolic blood pressure (SBP); C: Left 
Ventricular Developed Pressure (LVDP); D: Left ventricular end diastolic pressure (LVEDP). 
E: Min dp/dt; F: Max dp/dt; n=4-8. Mean±S.E.M. *p<0.05, **p<0.01, vs Sham; #p<0.05 vs 
ISO.  
4.3.4 Effect of H2S on plasma levels of lactate dehydrogenase (LDH)  
LDH is a surrogate marker for tissue breakdown in various diseases including myocardial 
infarction and HF. We measured LDH level to assess the extent of cardiac damage exerted by 
ISO. Evident in Figure 4.4, LDH level in ISO group was significantly elevated than that in 
the sham control, suggesting that ISO administration successfully induced cardiac injury. 
NaHS treatment significantly lowered LDH level, suggesting that H2S protected the heart 
against ISO-induced damages. 
 
Figure 4.4. NaHS treatment reversed ISO-induced LDH release and in rat plasma. n=6-8. 
Mean±S.E.M. **p<0.01 vs sham; #p<0.05 vs ISO. 
4.3.5 Effect of H2S on heart histology 
Sirus red stained sections showed an obvious interstitial collagen deposition (stained 
red) in ISO treated animals (Figure 4.5B) as compared to sham animals (Figure 4.5A). NaHS 
administration reduced ISO-induced collagen accumulation to a large extent (Figure 4.5C).    





Figure 4.5 Histological analysis of collagen deposition in heart tissues 2 weeks after ISO 
injection.  (A) Sham; (B) ISO-treated group; (C) ISO+NaHS treatment group. Paraffin-
embedded tissue sections were processed for Sirus Red staining for collagen (red) and 
connective tissue (yellow) labeling as described in “Materials and Methods”. Representative 
pictures were from three independent experiments.  
 
4.3.6 Effect of H2S on renin levels in plasma and left ventricles 
RAS plays important role in the development of HF and hypertrophy. We therefore 
examined renin levels in these animals. As shown in Figure 4.5, ISO treatment significantly 
increased renin levels in both plasma (Figure 4.6A) and LV tissues (Figure 4.6B), which were 
reversed by H2S treatment. These data suggest that H2S may produce beneficial effects 
through inhibition of renin activity. 
 
Figure 4.6 NaHS inhibits ISO-induced elevations of renin level in both plasma (A) and left 








4.3.7 Effect of H2S on renin expression and mast cell infiltration in LV 
In heart tissues, mast cells have been identified as the site for renin storage and 
synthesis. As such, we co-stained mast cells and renin using immunofluroscence microscopy 
as described previously176. As shown in Figure 4.7, ISO treatment significantly induced mast 
cell infiltration. Moreover, mast cells (green) overlap with renin (red) in LV sections, with 
enhanced expression in ISO group as compared to sham group. H2S treatment group showed 
reduced number of mast cells co-stained with renin as compared with ISO group. 
Figure 4.7 Immunohistochemistry showing the effect of H2S treatment on renin release and 
mast cell infiltration in the LV tissues in ISO-induced HF model. Increased number of renin-
containing mast cells and upregulated renin expression were found in the ISO group as 
compared with the sham group. NaHS treatment reduced mast cell count as well as renin 
expression in the LV tissues. Representative pictures were taken from three independent 
experiments. 
4.3.8 Effect of H2S on mast cell count in LV 
To quantify the number of mast cells across treatment groups, we stained heart tissue 
sections with the classical toluidine blue staining. ISO group (Figure 4.8B&D) showed 




significantly increased number of mast cells as compared with sham group (Figure 4.8A&D) 
whereas H2S treatment significantly attenuated this elevation (Figure 4.8C &D).  
 
Figure 4.8 Effect of NaHS treatment on the numbers of mast cells in LV sections stained with 
toluidine blue. Representative pictures (A-C) and group data (D) showed that treatment with 
H2S reduced mast cell infiltration into the LV of ISO-induced HF rats, while H2S by itself 
had no significant effect. n=4-12. Mean±SEM. ***p<0.001 vs Sham; #p<0.05 vs ISO. 
4.3.9 Effect of H2S on leukotriene B4 (LTB4) level and leukotriene A4 hydrolase (LTA4H) 
expression in LV 
In an effort to understand how H2S reduced mast cell count, we tested the level of a 
powerful chemoattractant for mast cells and its progenitors, LTB4. It was found that level of 
LTB4 was significantly elevated in cardiac tissues of ISO-treated animals. This is consistent 
with a previous publication200. H2S supplementation effectively attenuated this increment 
(Figure 4.9A). We further detected the protein expression of LTA4H, an enzyme responsible 
for the synthesis of LTB4. Our data showed that LTA4H was highly upregulated in ISO group, 
an effect that was significantly reversed by NaHS supplementation (Figure 4.9B).  Taken 
together, our data suggest that H2S may reduce LTB4 synthesis in mast cells via 




downregulation of LTA4H, and thus reduced infiltration of mast cells and progenitors from 
circulation into cardiac tissues.  
Figure 4.9 Effect of NaHS treatment on leukotriene B4 levels (A) and leukotriene A4 
hydrolase (LTA4H) expression (B) in cardiac LV tissues. n=5-14. Mean±SEM. *p<0.05 vs 
sham; #p<0.05 vs ISO. 
4.3.10 Effect of H2S treatment on mast cell degranulation in cardiac tissue 
Reclassification of toluidine blue stained cardiac mast cells into intact or degranulated 
cells revealed that there was no difference in intact mast cells across treatment groups (Figure 
4.10). However, the number of degranulated mast cells significantly increased in ISO treated 
animals, and NaHS treatment reversed this increment (Figure 4.10). These data strongly 
suggest that majority of total mast cell count increment in ISO group consist of degranulated 
mast cells mainly that are active in secretion of intracellular contents.          
 




Figure 4.10 ISO significantly increased degranulated mast cells but had no obvious effect on 
intact cells in the LV sections. NaHS treatment significantly reduced the number of 
degranulated cells in the LV of ISO-treated rats. n=4-12. Mean±SEM. **p<0.01 vs Control; 
#p<0.05 vs ISO.  
4.4 Discussion 
Mast cells are tissue-resident cells derived from hemopoietic stem cells in bone 
marrow, and cell maturation occurs within destined tissues after cell infiltration into tissues201. 
Cardiac mast cells have been reported to be the local site of renin synthesis, storage and 
release in the heart182, 183, and renin has been implicated in ventricular remodelling via 
multiple mechanisms178. Over the past decades, accumulating evidence has associated these 
cells with heart pathology202-205.  
We found in the present chapter, injection of ISO (150 mg/kg) significantly increased 
plasma LDH level and hypertrophy index along with impaired heart functions. Treatment 
with H2S attenuated the development of ISO-induced heart dysfunction. Histological staining 
showed that H2S decreased ISO-induced collagen deposition. Moreover, H2S treatment 
reversed ISO-induced renin elevation in both plasma and left ventricles.  
Immunohistochemistry of LV tissues showed that ISO administration led to increased 
abundance of renin-containing mast cells. Closer examination of mast cells revealed that 
there was no significant change in intact mast cell count across different treatment groups, 
but degranulated cell count. Accumulation of mast cells within tissues can be observed under 
many pathophysiological conditions as a result of directed migration in response to 
chemoattractants206. Intriguingly, mast cells can produce and secrete various chemoattractants 
on its own, thus attract more mast cells via autocrine and paracrine signaling 206.  
LTB4 is a potent chemoattractant for mast cells 206. We detected elevated levels of 
LTB4 as well as its synthesizing enzyme, LTA4H, in ISO-treated animals, contributing 
towards the increased number of mast cells attracted to the injured cardiac tissue200. Daily 




administration of NaHS to ISO-treated animals attenuated the numbers of mast cell count by 
lowering LTA4H and LTB4 levels, thereby lowering the infiltration of mast cells and 
progenitors into cardiac tissues.  
 








To further explore the effect of H2S on mast cells, we tested the effect of H2S on renin 
release in human mast cell line, HMC-1.1. HMC-1.1 expresses both renin mRNA and renin 
proteins that are 100% homologous to Homo sapiens 183, hence is capable of synthesizing and 
releasing renin 183. 
5.2 Methods and Materials 
5.2.1 Human Mast Cells (HMC-1.1)  
The human mastocytoma cell line, HMC-1.1, was kindly provided by J.H. Butterfield 
(Mayo Clinic, Rochester, MN). Cells were maintained in suspension culture at high density in 
Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 10% FBS and 1.2 
mmol/L monothioglycerol and kept at 37oC, 5% CO2.  
5.2.2 Immunostaining for renin, mast cells and cell nuclei  
To verify that the human mast cell line (HMC-1.1) used in the current study contains 
renin, these free floating cells were fixed in 3.7% formaldehyde for 10 minutes and 
permeabilized in 0.1% Triton X-100 (in PBS) for 2 minutes. After centrifugation, cells were 
resuspended in PBS and loaded onto funnel chamber (Thermo Shandon Cytofunnel) to be 
spun onto glass slides with Shandon Cytospin 4 cytocentrifudge (Thermo Scientific). 
Immunostaining procedures followed as described previously 14, 188.  
 





Figure 5.1 Triple-staining of mast cells, renin and cell nucleus in HMC-1.1 mast cells.  
Immunofluorescence chemistry revealed co-localization of (A) renin, (B) mast cells and (C) 
cell nucleus in HMC-1.1 cells. Viewed under 400X magnification.  
 
5.2.3 Renin and cAMP assays 
HMC-1.1 cells were treated with NaHS (10 µM) for 15 minutes before incubation 
with forskolin (50 µM) for 20 minutes. Cells were then centrifuged at 800 g for 5 minutes 
before supernatant and cell pellet were collected. Cell pellet will be suspended in lysis buffer 
and shaken on ice for one hour before centrifuged at 13000 g for 20 minutes. 
Renin activity in cell supernatants was determined using renin activity assay 
(SensoLyte® 390 Renin Assay Kit, Anaspec)196. Procedures were carried out following 
manufacturer’s instructions with slight deviations. Briefly, renin substrate solution 
(component A) was added to 50 µl of each sample and fluorescence intensity was recorded at 
Ex/Em=330 nm/390 nm. Renin from samples cleaved Mc-Ala/Dnp fluorescence resonance 
energy transfer (FRET) peptides to restore the fluorescence of Mc-Ala, which was otherwise 
quenched by Dnp. As such, fluorescence intensities recorded is directly proportional to renin 
activity in these samples, and this method has sensitivity of 8ng/ml for renin.  
cAMP ELISA assay was carried out following manufacturer’s instructions using 








5.2.4 Statistical Analysis 
All data are expressed as means ± SEM. Statistical comparisons among different 
treatment groups were tested using one-way ANOVA followed by a post hoc analysis 
(Turkey’s). Significance level was set at p<0.05 unless otherwise stated.  
 
5.3 Results 
5.3.1 H2S inhibited renin release from human mast cells 
HMC-1.1 expresses both renin mRNA and proteins, we therefore studied whether H2S 
can inhibit renin release from HMC-1.1. When HMC-1.1 cells were treated with forskolin, an 
adenylyl cyclase activator, renin was released from cell granules into supernatant. This is in 
line with a previous work207. Assay of supernatant medium showed elevations in renin 
activity (Figure 5.1) in forskolin-treated cells, whereas NaHS (10 µM) significantly decreased 
renin activity in the medium.  
 
Figure 5.2 Forskolin (50 μM) stimulated renin release from HMC- 1.1 into culture medium, 
but this effect was attenuated by NaHS (10 µM) treatment for 15 minutes. n=9. Mean±SEM. 
*p<0.05 vs Control; #p<0.05 vs forskolin.  
5.3.2 H2S inhibits renin release from human mast cells via lowering cAMP levels  
We then further investigated the level of cAMP level, and found that H2S attenuated 
forskolin-induced cAMP level (Figure 5.3). These data suggest that H2S is capable of 
inhibiting renin release via lowering cAMP level. 





Figure 5.3 NaHS treatment (10 µM) attenuated forskolin (50 µM) induced cAMP elevation in 
HMC-1.1. n=10-11. Mean±SEM. *p<0.05 vs Control; #p<0.05 vs forskolin.  
 
5.4 Discussion  
H2S has been implicated in cardioprotection against heart failure development but the 
underlying mechanism is not fully understood. Previous reports suggested that H2S may 
protect against HF and prevent hypertrophy via induction of anti-oxidant responses, 
inhibiting apoptosis and promoting angiogensis52.  
For the first time, we demonstrated that H2S could inhibit accumulation of cardiac 
mast cells (by attenuating mast cell chemoattractant LTB4 and its precursor enzyme LTAH4) 
and renin release (via downregulation of cAMP) to contribute against heart 
dysfunction/remodeling.  
In this chapter, we demonstrated that H2S inhibits renin release from mast cells by 
attenuating cAMP levels. This is consistent with our findings using renin-rich granular cells 
(chapter 3)148, 188. Collectively, our data suggest that H2S prevents renin release via 
prevention of cAMP elevation, thus exerting its protective effects against renin-dependent 
renal hypertension and heart failure. Our findings provide valuable insights into H2S induced 
protection and may further add on to our current understanding of H2S biology. 
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